Trial Outcomes & Findings for Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A) (NCT NCT00430521)

Last Updated: 2019-10-28

Results Overview

The seropositivity cut-off for the assay was an antibody titer equal to or above (≥) 1:10, in the sera of subjects seronegative before vaccination. The flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004, for adults who received the booster dose at Month 6.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

512 participants

Primary outcome timeframe

At Day 0

Results posted on

2019-10-28

Participant Flow

Participant milestones

Participant milestones
Measure	GSK1562902A V/I/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6.The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
Overall Study STARTED	63	66	64	63	64	64	65	63
Overall Study COMPLETED	52	57	61	55	59	59	55	51
Overall Study NOT COMPLETED	11	9	3	8	5	5	10	12

Reasons for withdrawal

Reasons for withdrawal
Measure	GSK1562902A V/I/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6.The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
Overall Study Adverse Event	0	0	0	0	0	2	1	0
Overall Study Lost to Follow-up	7	8	3	5	5	2	8	10
Overall Study Pregnancy	0	0	0	0	0	0	1	0
Overall Study Vaccine Expired	0	0	0	0	0	1	0	0
Overall Study Protocol Violation	1	0	0	0	0	0	0	0
Overall Study Withdrawal by Subject	3	1	0	3	0	0	0	2

Baseline Characteristics

Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	GSK1562902A V/I/6 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=66 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6.The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group n=65 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	Total n=512 Participants Total of all reporting groups
Age, Continuous	34.6 Years STANDARD_DEVIATION 12.9 • n=39 Participants	33.1 Years STANDARD_DEVIATION 11.4 • n=41 Participants	33.8 Years STANDARD_DEVIATION 11.8 • n=35 Participants	33.4 Years STANDARD_DEVIATION 12.4 • n=31 Participants	34.6 Years STANDARD_DEVIATION 12.9 • n=146 Participants	34.8 Years STANDARD_DEVIATION 12.9 • n=19 Participants	33.2 Years STANDARD_DEVIATION 11.2 • n=147 Participants	34.3 Years STANDARD_DEVIATION 11.6 • n=193 Participants	34.0 Years STANDARD_DEVIATION 12.1
Sex: Female, Male Female	32 Participants n=39 Participants	35 Participants n=41 Participants	33 Participants n=35 Participants	37 Participants n=31 Participants	37 Participants n=146 Participants	27 Participants n=19 Participants	36 Participants n=147 Participants	36 Participants n=193 Participants	273 Participants
Sex: Female, Male Male	31 Participants n=39 Participants	31 Participants n=41 Participants	31 Participants n=35 Participants	26 Participants n=31 Participants	27 Participants n=146 Participants	37 Participants n=19 Participants	29 Participants n=147 Participants	27 Participants n=193 Participants	239 Participants
Race/Ethnicity, Customized Caucasian / European heritage	63 Participants n=39 Participants	64 Participants n=41 Participants	62 Participants n=35 Participants	61 Participants n=31 Participants	64 Participants n=146 Participants	61 Participants n=19 Participants	63 Participants n=147 Participants	62 Participants n=193 Participants	500 Participants
Race/Ethnicity, Customized Others	0 Participants n=39 Participants	2 Participants n=41 Participants	2 Participants n=35 Participants	2 Participants n=31 Participants	0 Participants n=146 Participants	3 Participants n=19 Participants	2 Participants n=147 Participants	1 Participants n=193 Participants	12 Participants

PRIMARY outcome

Timeframe: At Day 0

Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=56 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=50 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value A/Indonesia, Day 0	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value A/Vietnam, Day 0	0 Participants	2 Participants	1 Participants	2 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value A/Vietnam, Month 6	25 Participants	18 Participants	35 Participants	34 Participants	—	—	—	—
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value A/Indonesia, Month 6	4 Participants	2 Participants	18 Participants	13 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 7 Days

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=45 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value A/Indonesia, Month 6 + 7 Days	52 Participants	37 Participants	41 Participants	37 Participants	—	—	—	—
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value A/Vietnam, Month 6 + 7 Days	52 Participants	42 Participants	43 Participants	41 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 21 Days

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=52 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value A/Indonesia, Month 6 + 21 Days	51 Participants	41 Participants	47 Participants	41 Participants	—	—	—	—
Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value A/Vietnam, Month 6 + 21 Days	51 Participants	43 Participants	47 Participants	43 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Day 0

GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains, for the groups who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=56 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=50 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies A/Indonesia, Day 0	5.0 Titers Interval 5.0 to 5.0	5.0 Titers Interval 5.0 to 5.0	5.0 Titers Interval 5.0 to 5.0	5.0 Titers Interval 5.0 to 5.0	—	—	—	—
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies A/Vietnam, Day 0	5.0 Titers Interval 5.0 to 5.0	5.3 Titers Interval 4.9 to 5.7	5.2 Titers Interval 4.8 to 5.7	5.7 Titers Interval 4.7 to 7.0	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6

GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains, for the groups who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies A/Vietnam, Month 6	12.0 Titers Interval 8.9 to 16.1	9.7 Titers Interval 7.4 to 12.7	29.9 Titers Interval 20.1 to 44.4	32.0 Titers Interval 21.3 to 48.0	—	—	—	—
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies A/Indonesia, Month 6	5.5 Titers Interval 5.0 to 6.0	5.3 Titers Interval 4.9 to 5.7	8.6 Titers Interval 6.6 to 11.3	7.2 Titers Interval 6.0 to 8.6	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 7 Days

GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains, for the groups who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=45 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies A/Indonesia, Month 6 + 7 days	152.9 Titers Interval 112.2 to 208.2	64.6 Titers Interval 41.3 to 101.1	120.0 Titers Interval 76.8 to 187.6	65.0 Titers Interval 42.1 to 100.2	—	—	—	—
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies A/Vietnam, Month 6 + 7 days	226.3 Titers Interval 168.3 to 304.3	202.6 Titers Interval 130.7 to 314.1	182.7 Titers Interval 118.5 to 281.7	224.5 Titers Interval 144.9 to 347.7	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 21 Days

GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains, for the groups who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=52 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies A/Indonesia, Month 6 + 21 Days	303.4 Titers Interval 215.7 to 426.6	92.4 Titers Interval 61.1 to 139.9	392.9 Titers Interval 256.7 to 601.4	127.7 Titers Interval 83.8 to 194.6	—	—	—	—
Geometric Mean Titers (GMTs) of H5N1 HI Antibodies A/Vietnam, Month 6 + 21 Days	434.7 Titers Interval 314.8 to 600.5	287.2 Titers Interval 180.3 to 457.5	571.4 Titers Interval 366.3 to 891.3	380.5 Titers Interval 240.2 to 602.9	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6

The seroconversion factor (SCF) was defined as the fold change in serum H5N1 HI geometric mean titers (GMTs) post-vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6	1.1 Fold Increase Interval 1.0 to 1.2	1.1 Fold Increase Interval 1.0 to 1.1	1.7 Fold Increase Interval 1.3 to 2.3	1.4 Fold Increase Interval 1.2 to 1.7	—	—	—	—
Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6	2.4 Fold Increase Interval 1.8 to 3.2	1.8 Fold Increase Interval 1.4 to 2.4	6.0 Fold Increase Interval 4.0 to 8.9	5.6 Fold Increase Interval 3.8 to 8.2	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 7 Days

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=45 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6 + 7 Days	30.6 Fold Increase Interval 22.4 to 41.6	12.9 Fold Increase Interval 8.3 to 20.2	24.0 Fold Increase Interval 15.4 to 37.5	13.0 Fold Increase Interval 8.4 to 20.0	—	—	—	—
Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6 + 7 Days	45.3 Fold Increase Interval 33.7 to 60.9	38.2 Fold Increase Interval 23.7 to 56.3	36.5 Fold Increase Interval 23.7 to 56.3	38.8 Fold Increase Interval 24.7 to 60.9	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 21 Days

The seroconversion factor (SCF) was defined as the fold change in serum H5N1 HI geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=52 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6 + 21 Days	60.7 Fold Increase Interval 43.1 to 85.3	18.5 Fold Increase Interval 12.2 to 28.0	78.6 Fold Increase Interval 51.3 to 120.3	25.5 Fold Increase Interval 16.8 to 38.9	—	—	—	—
Seroconversion Factor for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6 + 21 Days	86.9 Fold Increase Interval 63.0 to 120.1	54.2 Fold Increase Interval 33.8 to 87.1	114.3 Fold Increase Interval 73.3 to 178.3	66.0 Fold Increase Interval 41.2 to 105.7	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6

A seroconverted (SCR) subject was defined as a vaccinated subject who had either a pre-vaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6	0 Participants	0 Participants	5 Participants	2 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6	14 Participants	6 Participants	26 Participants	27 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 7 Days

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=45 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6 + 7 Days	49 Participants	35 Participants	40 Participants	33 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6 + 7 Days	52 Participants	42 Participants	42 Participants	39 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 21 Days

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=52 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6 + 21 Days	51 Participants	40 Participants	46 Participants	40 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6 + 21 Days	51 Participants	43 Participants	46 Participants	42 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Day 0

A seroprotected (SPR) subject was defined as a vaccinated subject with serum H5N1 HI titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=56 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=50 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Day 0	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Day 0	0 Participants	0 Participants	1 Participants	2 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6	0 Participants	0 Participants	5 Participants	2 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6	14 Participants	7 Participants	26 Participants	28 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 7 Days

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=45 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6 + 7 Days	49 Participants	35 Participants	40 Participants	33 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6 + 7 Days	52 Participants	42 Participants	42 Participants	40 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 21 Days

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=52 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6 + 21 Days	51 Participants	40 Participants	46 Participants	40 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 Haemagglutination-inhibition (HI) Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6 + 21 Days	51 Participants	43 Participants	46 Participants	42 Participants	—	—	—	—

PRIMARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses, up to 6/12 months + 7 days

Population: This analysis was performed on the Total vaccinated Cohort, which included all vaccinated subjects for whom data were available and who had their symptom sheets filled in. The data for Dose 3 were not collected from subjects who did not receive the booster dose, given at either Month 6 or Month 12.

Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/induration/redness/swelling = spreading beyond 100 millimeters (mm) of injection site.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=62 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=66 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=62 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group n=65 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Ecchymosis, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Swelling, Dose 2	7 Participants	12 Participants	10 Participants	10 Participants	6 Participants	7 Participants	4 Participants	10 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Ecchymosis, Across doses	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Induration, Across doses	17 Participants	13 Participants	22 Participants	25 Participants	14 Participants	16 Participants	24 Participants	19 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Swelling, Dose 2	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Induration, Across doses	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Pain, Across doses	56 Participants	62 Participants	61 Participants	59 Participants	61 Participants	57 Participants	62 Participants	58 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Pain, Across doses	6 Participants	6 Participants	5 Participants	10 Participants	8 Participants	8 Participants	5 Participants	5 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Redness, Across doses	11 Participants	8 Participants	16 Participants	13 Participants	8 Participants	11 Participants	13 Participants	15 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Redness, Across doses	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Swelling, Across doses	12 Participants	15 Participants	21 Participants	22 Participants	10 Participants	13 Participants	16 Participants	16 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Swelling, Across doses	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Ecchymosis, Dose 1	1 Participants	1 Participants	2 Participants	0 Participants	0 Participants	0 Participants	3 Participants	1 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Induration, Dose 1	9 Participants	9 Participants	10 Participants	20 Participants	7 Participants	9 Participants	14 Participants	8 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Induration, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Pain, Dose 1	50 Participants	61 Participants	54 Participants	56 Participants	53 Participants	52 Participants	57 Participants	54 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Pain, Dose 1	2 Participants	2 Participants	0 Participants	4 Participants	5 Participants	5 Participants	2 Participants	1 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Redness, Dose 1	4 Participants	6 Participants	5 Participants	8 Participants	5 Participants	8 Participants	6 Participants	5 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Redness, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Swelling, Dose 1	7 Participants	7 Participants	7 Participants	14 Participants	5 Participants	10 Participants	8 Participants	9 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Swelling, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Ecchymosis, Dose 2	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	2 Participants	1 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Ecchymosis, Dose 2	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Induration, Dose 2	13 Participants	11 Participants	9 Participants	14 Participants	11 Participants	11 Participants	9 Participants	8 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Induration, Dose 2	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Pain, Dose 2	46 Participants	49 Participants	50 Participants	49 Participants	54 Participants	47 Participants	49 Participants	47 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Pain, Dose 2	4 Participants	4 Participants	0 Participants	4 Participants	4 Participants	3 Participants	0 Participants	1 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Redness, Dose 2	9 Participants	8 Participants	11 Participants	7 Participants	5 Participants	7 Participants	7 Participants	8 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Redness, Dose 2	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Ecchymosis, Dose 3	—	—	0 Participants	0 Participants	—	—	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Ecchymosis, Dose 3	—	—	0 Participants	0 Participants	—	—	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Induration, Dose 3	—	—	16 Participants	13 Participants	—	—	15 Participants	10 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Induration, Dose 3	—	—	0 Participants	0 Participants	—	—	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Pain, Dose 3	—	—	53 Participants	51 Participants	—	—	48 Participants	44 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Pain, Dose 3	—	—	5 Participants	5 Participants	—	—	4 Participants	4 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Redness, Dose 3	—	—	8 Participants	7 Participants	—	—	8 Participants	8 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Redness, Dose 3	—	—	0 Participants	0 Participants	—	—	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Swelling, Dose 3	—	—	15 Participants	13 Participants	—	—	10 Participants	8 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Grade 3 Swelling, Dose 3	—	—	0 Participants	0 Participants	—	—	0 Participants	0 Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms Any Ecchymosis, Across doses	2 Participants	1 Participants	2 Participants	1 Participants	0 Participants	2 Participants	4 Participants	1 Participants

PRIMARY outcome

Timeframe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses, up to 12 months + 7 days

Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature above (\>) 38 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 40.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=62 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=66 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=62 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group n=65 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Shivering, Dose 1	13 Participants	12 Participants	10 Participants	21 Participants	15 Participants	8 Participants	9 Participants	14 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Shivering, Dose 1	3 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Shivering, Dose 1	13 Participants	11 Participants	8 Participants	19 Participants	14 Participants	8 Participants	6 Participants	13 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Sweating, Dose 1	5 Participants	7 Participants	8 Participants	10 Participants	5 Participants	1 Participants	4 Participants	12 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Arthralgia, Dose 2	12 Participants	20 Participants	11 Participants	13 Participants	14 Participants	12 Participants	15 Participants	15 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Sweating, Dose 2	1 Participants	1 Participants	0 Participants	0 Participants	1 Participants	1 Participants	2 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Arthralgia, Dose 3	—	—	17 Participants	16 Participants	—	—	17 Participants	13 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Fatigue, Dose 3	—	—	28 Participants	27 Participants	—	—	24 Participants	28 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Headache, Dose 3	—	—	1 Participants	4 Participants	—	—	1 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Arthralgia, Across doses	17 Participants	25 Participants	27 Participants	28 Participants	20 Participants	13 Participants	29 Participants	26 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Arthralgia, Across doses	16 Participants	22 Participants	26 Participants	25 Participants	20 Participants	12 Participants	25 Participants	24 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Fatigue, Across doses	33 Participants	34 Participants	42 Participants	38 Participants	36 Participants	31 Participants	40 Participants	42 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Fever, Across doses	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Headache, Across doses	34 Participants	31 Participants	41 Participants	41 Participants	31 Participants	34 Participants	45 Participants	41 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Headache, Across doses	31 Participants	28 Participants	36 Participants	38 Participants	30 Participants	30 Participants	41 Participants	35 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Myalgia, Across doses	41 Participants	41 Participants	47 Participants	48 Participants	49 Participants	41 Participants	45 Participants	47 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Myalgia, Across doses	5 Participants	3 Participants	2 Participants	4 Participants	4 Participants	3 Participants	7 Participants	4 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Myalgia, Across doses	39 Participants	38 Participants	46 Participants	47 Participants	45 Participants	39 Participants	43 Participants	43 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Shivering, Across doses	6 Participants	3 Participants	3 Participants	5 Participants	4 Participants	2 Participants	4 Participants	4 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Shivering, Across doses	21 Participants	26 Participants	21 Participants	34 Participants	22 Participants	19 Participants	23 Participants	29 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Sweating, Across doses	15 Participants	18 Participants	23 Participants	20 Participants	16 Participants	7 Participants	23 Participants	25 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Sweating, Across doses	1 Participants	1 Participants	1 Participants	3 Participants	1 Participants	1 Participants	3 Participants	1 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Sweating, Across doses	13 Participants	15 Participants	21 Participants	17 Participants	15 Participants	6 Participants	21 Participants	24 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Arthralgia, Dose 2	12 Participants	16 Participants	9 Participants	12 Participants	14 Participants	11 Participants	13 Participants	14 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Arthralgia, Dose 1	8 Participants	12 Participants	11 Participants	15 Participants	13 Participants	9 Participants	8 Participants	6 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Arthralgia, Dose 1	2 Participants	1 Participants	0 Participants	0 Participants	2 Participants	0 Participants	1 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Arthralgia, Dose 1	7 Participants	12 Participants	9 Participants	12 Participants	13 Participants	8 Participants	6 Participants	6 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Fatigue, Dose 1	25 Participants	27 Participants	24 Participants	26 Participants	27 Participants	21 Participants	25 Participants	25 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Fatigue, Dose 1	0 Participants	1 Participants	2 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Fatigue, Dose 1	24 Participants	25 Participants	20 Participants	20 Participants	27 Participants	19 Participants	19 Participants	23 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Fever, Dose 1	4 Participants	3 Participants	0 Participants	1 Participants	0 Participants	1 Participants	1 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Fever, Dose 1	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Fever, Dose 1	4 Participants	3 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Headache, Dose 1	22 Participants	18 Participants	19 Participants	25 Participants	18 Participants	24 Participants	28 Participants	20 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Headache, Dose 1	3 Participants	0 Participants	0 Participants	4 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Headache, Dose 1	21 Participants	15 Participants	18 Participants	21 Participants	17 Participants	21 Participants	23 Participants	19 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Myalgia, Dose 1	29 Participants	29 Participants	31 Participants	32 Participants	31 Participants	29 Participants	27 Participants	31 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Myalgia, Dose 1	3 Participants	1 Participants	0 Participants	0 Participants	2 Participants	1 Participants	2 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Myalgia, Dose 1	29 Participants	26 Participants	29 Participants	30 Participants	30 Participants	27 Participants	26 Participants	29 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Sweating, Dose 1	6 Participants	7 Participants	9 Participants	12 Participants	5 Participants	2 Participants	5 Participants	12 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Sweating, Dose 1	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Arthralgia, Dose 2	1 Participants	1 Participants	0 Participants	1 Participants	1 Participants	1 Participants	3 Participants	1 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Fatigue, Dose 2	23 Participants	27 Participants	28 Participants	21 Participants	30 Participants	22 Participants	21 Participants	27 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Fatigue, Dose 2	2 Participants	1 Participants	0 Participants	0 Participants	5 Participants	3 Participants	4 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Fatigue, Dose 2	20 Participants	24 Participants	25 Participants	19 Participants	28 Participants	22 Participants	18 Participants	26 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Fever, Dose 2	2 Participants	2 Participants	1 Participants	0 Participants	4 Participants	3 Participants	1 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Fever, Dose 2	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Fever, Dose 2	2 Participants	2 Participants	1 Participants	0 Participants	4 Participants	2 Participants	1 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Headache, Dose 2	22 Participants	22 Participants	24 Participants	26 Participants	24 Participants	22 Participants	20 Participants	15 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Headache, Dose 2	1 Participants	2 Participants	0 Participants	3 Participants	1 Participants	2 Participants	1 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Headache, Dose 2	18 Participants	19 Participants	18 Participants	22 Participants	23 Participants	20 Participants	16 Participants	13 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Myalgia, Dose 2	28 Participants	32 Participants	27 Participants	22 Participants	40 Participants	30 Participants	29 Participants	28 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Myalgia, Dose 2	2 Participants	2 Participants	0 Participants	1 Participants	3 Participants	2 Participants	3 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Myalgia, Dose 2	25 Participants	27 Participants	23 Participants	21 Participants	37 Participants	26 Participants	28 Participants	25 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Shivering, Dose 2	14 Participants	21 Participants	10 Participants	13 Participants	17 Participants	14 Participants	9 Participants	14 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Shivering, Dose 2	3 Participants	2 Participants	1 Participants	1 Participants	4 Participants	2 Participants	2 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Shivering, Dose 2	12 Participants	19 Participants	9 Participants	13 Participants	17 Participants	14 Participants	8 Participants	14 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Sweating, Dose 2	10 Participants	12 Participants	12 Participants	5 Participants	13 Participants	6 Participants	12 Participants	7 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Sweating, Dose 2	8 Participants	9 Participants	12 Participants	4 Participants	12 Participants	6 Participants	10 Participants	6 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Arthralgia, Dose 3	—	—	18 Participants	19 Participants	—	—	19 Participants	14 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Arthralgia, Dose 3	—	—	0 Participants	3 Participants	—	—	4 Participants	1 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Fatigue, Dose 3	—	—	32 Participants	30 Participants	—	—	29 Participants	29 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Fatigue, Dose 3	—	—	2 Participants	3 Participants	—	—	0 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Fever, Dose 3	—	—	3 Participants	3 Participants	—	—	3 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Fever, Dose 3	—	—	0 Participants	0 Participants	—	—	0 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Fever, Dose 3	—	—	2 Participants	3 Participants	—	—	3 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Headache, Dose 3	—	—	30 Participants	28 Participants	—	—	23 Participants	32 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Headache, Dose 3	—	—	22 Participants	26 Participants	—	—	20 Participants	25 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Myalgia, Dose 3	—	—	35 Participants	36 Participants	—	—	31 Participants	29 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Myalgia, Dose 3	—	—	2 Participants	3 Participants	—	—	4 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Myalgia, Dose 3	—	—	31 Participants	33 Participants	—	—	28 Participants	27 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Shivering, Dose 3	—	—	17 Participants	19 Participants	—	—	18 Participants	21 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Shivering, Dose 3	—	—	3 Participants	4 Participants	—	—	2 Participants	3 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Shivering, Dose 3	—	—	15 Participants	17 Participants	—	—	17 Participants	21 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Sweating, Dose 3	—	—	13 Participants	13 Participants	—	—	11 Participants	15 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Sweating, Dose 3	—	—	1 Participants	2 Participants	—	—	1 Participants	0 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Sweating, Dose 3	—	—	11 Participants	12 Participants	—	—	10 Participants	13 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Shivering, Across doses	22 Participants	28 Participants	24 Participants	36 Participants	22 Participants	19 Participants	25 Participants	29 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Arthralgia, Across doses	3 Participants	2 Participants	0 Participants	4 Participants	3 Participants	1 Participants	5 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Fatigue, Across doses	35 Participants	37 Participants	45 Participants	44 Participants	37 Participants	33 Participants	47 Participants	44 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Fatigue, Across doses	2 Participants	2 Participants	3 Participants	3 Participants	5 Participants	4 Participants	4 Participants	2 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Any Fever, Across doses	6 Participants	4 Participants	4 Participants	4 Participants	4 Participants	4 Participants	4 Participants	5 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Related Fever, Across doses	6 Participants	4 Participants	3 Participants	3 Participants	4 Participants	2 Participants	4 Participants	5 Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Grade 3 Headache, Across doses	4 Participants	2 Participants	1 Participants	8 Participants	1 Participants	3 Participants	2 Participants	3 Participants

PRIMARY outcome

Timeframe: During the 30-day (Days 0-29) post-primary vaccination period (Month 6 + 30 days)

Population: This analysis was performed on the Total vaccinated Cohort, which included all vaccinated subjects for whom data were available.

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=66 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group n=65 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) Any AEs	31 Participants	19 Participants	32 Participants	28 Participants	18 Participants	10 Participants	19 Participants	24 Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) Grade 3 AEs	3 Participants	4 Participants	2 Participants	3 Participants	0 Participants	2 Participants	1 Participants	7 Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) Related AEs	12 Participants	11 Participants	11 Participants	15 Participants	5 Participants	3 Participants	6 Participants	6 Participants

PRIMARY outcome

Timeframe: During the 30-day (Days 0-29) post-booster vaccination period (Month 12 + 30 days)

Population: This analysis was performed on the Total vaccinated Cohort, which included all vaccinated subjects for whom data were available. Data were collected only for subjects who received the Month 12 vaccine dose.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group n=62 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group n=58 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group n=56 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) Any AE(s)	—	—	—	—	16 Participants	10 Participants	16 Participants	14 Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) Related AE(s)	—	—	—	—	7 Participants	4 Participants	9 Participants	9 Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) Grade 3 AE(s)	—	—	—	—	2 Participants	2 Participants	2 Participants	1 Participants

PRIMARY outcome

Timeframe: During the entire study period (Day 0 to Month 18)

Population: This analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects for whom data were available.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=66 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group n=65 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	35 Participants	23 Participants	32 Participants	31 Participants	27 Participants	24 Participants	30 Participants	31 Participants

PRIMARY outcome

Timeframe: During the entire study period (Day 0 to Month 18)

Population: This analysis was performed on the Total vaccinated Cohort, which included all vaccinated subjects for whom data were available.

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=66 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group n=65 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Subjects With Serious Adverse Events (SAEs)	4 Participants	1 Participants	0 Participants	3 Participants	1 Participants	5 Participants	1 Participants	3 Participants

PRIMARY outcome

Timeframe: At Month 6 + 7 Days

Booster seroconversion (SCR) was defined as: For seronegative subjects at pre-booster (Month 6), antibody titer ≥ 1:40 at Month 6 + 7 days; For seropositive subjects at pre-booster (Month 6), antibody titer at Month 6 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 6. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=45 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease A/Vietnam, Month 6 + 7 Days	47 Participants	40 Participants	31 Participants	30 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease A/Indonesia, Month 6 + 7 Days	48 Participants	35 Participants	40 Participants	31 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 21 days

Booster SCR was defined as: For seronegative subjects at pre-booster (Month 6), antibody titer ≥ 1:40 at Month 6 + 7 days; For seropositive subjects at pre-booster (Month 6), antibody titer at Month 6 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 6. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005, for adults who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=52 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease A/Indonesia, Month 6 + 21 Days	51 Participants	39 Participants	45 Participants	39 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease A/Vietnam, Month 6 + 21 Days	51 Participants	42 Participants	44 Participants	38 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 7 Days

Booster Factor (Seroconversion Factor booster) was defined as the fold change in H5N1 HI antibodies between the pre- and post-booster vaccination time-points (mean\[log10(POST/M6)\]). The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005, for groups who received the booster dose at Month 6.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=45 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6 + 7 Days	27.9 Fold Increase Interval 20.4 to 38.3	12.3 Fold Increase Interval 7.8 to 19.2	14.5 Fold Increase Interval 8.7 to 24.3	9.2 Fold Increase Interval 6.2 to 13.7	—	—	—	—
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6 + 7 Days	18.2 Fold Increase Interval 12.8 to 26.0	20.3 Fold Increase Interval 12.7 to 32.5	6.3 Fold Increase Interval 4.1 to 9.7	6.9 Fold Increase Interval 4.5 to 10.7	—	—	—	—

PRIMARY outcome

Timeframe: At Month 6 + 21 Days

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=52 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease A/Indonesia, Month 6 + 21 Days	55.3 Fold Increase Interval 39.5 to 77.4	17.6 Fold Increase Interval 11.5 to 26.8	45.6 Fold Increase Interval 30.8 to 67.4	17.9 Fold Increase Interval 11.9 to 27.0	—	—	—	—
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease A/Vietnam, Month 6 + 21 Days	35.4 Fold Increase Interval 24.5 to 51.1	29.2 Fold Increase Interval 18.2 to 46.6	19.1 Fold Increase Interval 12.4 to 29.4	11.5 Fold Increase Interval 7.3 to 18.0	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days and at Month 18

Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for Month 18), which included all evaluable subjects for whom immunogenicity were available and who complied with the inclusion/exclusion criteria defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.

GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=59 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=60 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 6	13.2 Titers Interval 9.3 to 18.7	10.6 Titers Interval 8.0 to 14.0	38.4 Titers Interval 26.6 to 55.5	24.0 Titers Interval 17.2 to 33.5	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Vietnam, Day 21	22.1 Titers Interval 14.5 to 33.8	17.6 Titers Interval 12.3 to 25.2	21.4 Titers Interval 14.3 to 32.0	15.8 Titers Interval 10.9 to 23.1	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Vietnam, Day 42	—	—	239.4 Titers Interval 157.2 to 364.8	178.3 Titers Interval 116.6 to 272.5	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 18	115.8 Titers Interval 71.9 to 186.3	76.1 Titers Interval 47.1 to 123.1	337.5 Titers Interval 219.5 to 518.9	149.3 Titers Interval 93.0 to 239.6	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Indonesia, Day 0	5.0 Titers Interval 5.0 to 5.0	5.0 Titers Interval 5.0 to 5.0	5.0 Titers Interval 5.0 to 5.0	5.0 Titers Interval 5.0 to 5.0	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Indonesia, Day 21	6.8 Titers Interval 5.5 to 8.3	6.3 Titers Interval 5.2 to 7.7	6.0 Titers Interval 5.2 to 6.8	5.3 Titers Interval 5.0 to 5.7	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Indonesia, Day 42	—	—	28.0 Titers Interval 18.0 to 43.6	18.6 Titers Interval 12.7 to 27.2	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 6	5.7 Titers Interval 5.1 to 6.4	5.4 Titers Interval 4.8 to 6.0	10.2 Titers Interval 7.8 to 13.3	6.5 Titers Interval 5.6 to 7.5	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12	5.8 Titers Interval 5.0 to 6.8	5.9 Titers Interval 5.1 to 6.8	5.7 Titers Interval 5.0 to 6.5	8.4 Titers Interval 6.4 to 11.1	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	97.8 Titers Interval 66.5 to 143.8	196.2 Titers Interval 128.6 to 299.2	106.5 Titers Interval 66.7 to 170.0	239.4 Titers Interval 149.9 to 382.2	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	139.3 Titers Interval 92.0 to 211.0	420.0 Titers Interval 283.8 to 621.6	191.9 Titers Interval 121.6 to 303.0	624.9 Titers Interval 469.3 to 831.9	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 18	139.3 Titers Interval 85.7 to 226.6	56.6 Titers Interval 35.5 to 90.2	385.9 Titers Interval 252.9 to 588.6	121.3 Titers Interval 76.6 to 192.0	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Vietnam, Day 0	5.0 Titers Interval 5.0 to 5.0	5.1 Titers Interval 4.9 to 5.4	5.1 Titers Interval 4.9 to 5.4	5.2 Titers Interval 4.8 to 5.5	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12	8.4 Titers Interval 6.4 to 11.0	9.9 Titers Interval 7.3 to 13.5	14.2 Titers Interval 10.1 to 20.1	17.4 Titers Interval 11.6 to 25.9	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	235.9 Titers Interval 153.7 to 362.1	354.3 Titers Interval 244.7 to 513.0	257.7 Titers Interval 162.4 to 409.0	358.2 Titers Interval 228.7 to 561.1	—	—	—	—
GMTs of H5N1 HI Antibodies Against 2 Strains of Influenza Disease for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	352.6 Titers Interval 229.9 to 540.8	662.2 Titers Interval 458.3 to 956.6	441.0 Titers Interval 279.5 to 695.9	942.2 Titers Interval 703.1 to 1262.7	—	—	—	—

SECONDARY outcome

Timeframe: At Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days

Population: This analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=59 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=60 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Day 42	—	—	24 Participants	20 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	40 Participants	44 Participants	34 Participants	39 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 6	15 Participants	10 Participants	35 Participants	24 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Day 21	5 Participants	3 Participants	1 Participants	0 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 6	0 Participants	1 Participants	7 Participants	1 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12	6 Participants	2 Participants	0 Participants	5 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	42 Participants	49 Participants	36 Participants	43 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Day 21	26 Participants	24 Participants	25 Participants	16 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Day 42	—	—	44 Participants	43 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12	6 Participants	10 Participants	9 Participants	17 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	45 Participants	49 Participants	37 Participants	40 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	46 Participants	50 Participants	38 Participants	43 Participants	—	—	—	—

SECONDARY outcome

Timeframe: At Month 12 + 7 Days, Month 12 + 21 Days and Month 18

Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Persistence, which included all evaluable subjects for whom ilong term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.

Seroconversion defined as: For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination; For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=40 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=40 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	46 Participants	39 Participants	40 Participants	36 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	43 Participants	41 Participants	35 Participants	34 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	40 Participants	37 Participants	36 Participants	34 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 18	39 Participants	34 Participants	37 Participants	34 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	47 Participants	42 Participants	40 Participants	37 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 18	30 Participants	33 Participants	34 Participants	29 Participants	—	—	—	—

SECONDARY outcome

Timeframe: At Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days

The seroconversion factor (SCF) was defined as the fold change in serum hemagglutination inhibition (HI) geometric mean titers (GMTs) post-vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/5/2005.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=59 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=57 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=52 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=51 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Month 6	1.1 Fold Increase Interval 1.0 to 1.3	1.1 Fold Increase Interval 1.0 to 1.2	2.0 Fold Increase Interval 1.6 to 2.7	1.3 Fold Increase Interval 1.1 to 1.5	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Month 12	2.0 Fold Increase Interval 1.5 to 2.7	1.6 Fold Increase Interval 1.3 to 2.1	3.5 Fold Increase Interval 2.3 to 5.2	2.7 Fold Increase Interval 1.9 to 3.9	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	70.9 Fold Increase Interval 48.9 to 102.6	45.9 Fold Increase Interval 29.8 to 70.7	71.6 Fold Increase Interval 45.7 to 112.2	49.4 Fold Increase Interval 31.0 to 78.6	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	132.4 Fold Increase Interval 91.7 to 191.3	68.6 Fold Increase Interval 44.5 to 105.8	188.4 Fold Increase Interval 140.6 to 252.5	84.5 Fold Increase Interval 53.3 to 133.9	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Day 21	1.4 Fold Increase Interval 1.1 to 1.7	1.3 Fold Increase Interval 1.0 to 1.6	1.2 Fold Increase Interval 1.0 to 1.3	1.1 Fold Increase Interval 1.0 to 1.2	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Day 42	—	—	5.9 Fold Increase Interval 3.6 to 9.5	3.6 Fold Increase Interval 2.5 to 5.3	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Month 12	1.2 Fold Increase Interval 1.0 to 1.2	1.2 Fold Increase Interval 1.0 to 1.2	1.7 Fold Increase Interval 1.3 to 2.2	1.1 Fold Increase Interval 1.0 to 1.3	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	39.2 Fold Increase Interval 25.7 to 59.8	19.6 Fold Increase Interval 13.3 to 28.8	47.9 Fold Increase Interval 30.0 to 76.4	21.3 Fold Increase Interval 13.3 to 34.0	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	84.0 Fold Increase Interval 56.8 to 124.3	27.9 Fold Increase Interval 18.4 to 42.2	125.0 Fold Increase Interval 93.9 to 166.4	38.4 Fold Increase Interval 24.3 to 60.6	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Day 21	4.1 Fold Increase Interval 2.6 to 6.3	3.6 Fold Increase Interval 2.5 to 5.2	3.8 Fold Increase Interval 2.5 to 5.6	3.2 Fold Increase Interval 2.2 to 4.8	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Day 42	—	—	45.6 Fold Increase Interval 28.4 to 73.4	34.4 Fold Increase Interval 22.7 to 52.2	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Month 6	2.6 Fold Increase Interval 1.9 to 3.7	2.1 Fold Increase Interval 1.6 to 2.7	7.5 Fold Increase Interval 5.2 to 10.8	4.6 Fold Increase Interval 3.4 to 6.4	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days

A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=59 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=60 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Day 0	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Day 42	—	—	24 Participants	20 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Month 12	2 Participants	2 Participants	0 Participants	5 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	40 Participants	44 Participants	34 Participants	39 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	42 Participants	49 Participants	36 Participants	43 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Day 0	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Day 21	26 Participants	24 Participants	25 Participants	17 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Day 42	—	—	45 Participants	43 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Month 6	15 Participants	10 Participants	36 Participants	24 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Month 12	6 Participants	10 Participants	9 Participants	17 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Month 12 + 7 days	45 Participants	49 Participants	37 Participants	40 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	46 Participants	50 Participants	38 Participants	43 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Day 21	5 Participants	3 Participants	1 Participants	0 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 12 A/Indonesia, Month 6	0 Participants	1 Participants	7 Participants	1 Participants	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0, Day 21, Day 42, Month 6, Month 6+ 7 Days, Month 6+ 21 Days, Month 12 and at Month 18

Population: This analysis was performed on the According-to-Protocol (ATP) Cohort for Persistence, which included all evaluable subjects for whom long term immunogenicity data were available and who complied with the inclusion/exclusion criteria defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.

GMTs were calculated for H5N1 HI antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=51 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=44 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 21	6.5 Titers Interval 5.4 to 7.7	5.6 Titers Interval 5.1 to 6.0	6.3 Titers Interval 5.2 to 7.6	5.4 Titers Interval 5.0 to 5.8	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 42	—	—	22.5 Titers Interval 14.8 to 34.3	16.7 Titers Interval 10.8 to 25.8	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6	5.5 Titers Interval 5.0 to 6.1	5.3 Titers Interval 4.9 to 5.7	8.5 Titers Interval 6.4 to 11.2	7.0 Titers Interval 5.8 to 8.4	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 7 Days	142.6 Titers Interval 102.7 to 197.9	64.5 Titers Interval 40.1 to 103.7	124.1 Titers Interval 75.2 to 204.8	59.9 Titers Interval 38.1 to 94.3	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 21 Days	290.8 Titers Interval 202.1 to 418.3	97.9 Titers Interval 63.3 to 151.2	383.5 Titers Interval 245.2 to 599.7	120.9 Titers Interval 76.9 to 190.1	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 12	44.6 Titers Interval 28.6 to 69.5	17.6 Titers Interval 11.8 to 26.2	56.6 Titers Interval 33.7 to 95.0	23.8 Titers Interval 14.5 to 38.9	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 18	31.1 Titers Interval 20.3 to 47.5	19.8 Titers Interval 13.3 to 29.7	50.6 Titers Interval 32.0 to 79.9	28.3 Titers Interval 17.0 to 47.0	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 0	5.0 Titers Interval 5.0 to 5.0	5.2 Titers Interval 5.2 to 5.6	5.2 Titers Interval 4.8 to 5.7	5.8 Titers Interval 4.7 to 7.2	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 21	20.7 Titers Interval 13.9 to 30.7	15.8 Titers Interval 10.9 to 23.0	34.3 Titers Interval 21.4 to 55.0	30.8 Titers Interval 18.2 to 52.2	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 42	—	—	220.6 Titers Interval 145.4 to 334.6	275.1 Titers Interval 178.2 to 424.7	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6	11.6 Titers Interval 8.6 to 15.5	9.7 Titers Interval 7.3 to 12.9	29.6 Titers Interval 19.7 to 44.4	31.3 Titers Interval 20.2 to 48.5	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 7 Days	209.0 Titers Interval 152.7 to 286.2	215.4 Titers Interval 137.8 to 336.6	191.0 Titers Interval 117.3 to 311.0	211.7 Titers Interval 133.0 to 337.0	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 21 Days	411.1 Titers Interval 291.3 to 580.3	317.4 Titers Interval 197.5 to 510.1	542.1 Titers Interval 340.8 to 862.5	359.2 Titers Interval 220.2 to 585.9	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 18	24.3 Titers Interval 16.3 to 36.4	25.7 Titers Interval 16.3 to 40.4	45.1 Titers Interval 28.8 to 70.7	46.4 Titers Interval 27.7 to 77.7	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 0	5.0 Titers Interval 5.0 to 5.0	5.0 Titers Interval 5.0 to 5.0	5.0 Titers Interval 5.0 to 5.0	5.0 Titers Interval 5.0 to 5.0	—	—	—	—
GMTs of H5N1 HI Antibody Titers, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 12	66.0 Titers Interval 43.0 to 101.1	63.8 Titers Interval 40.6 to 100.3	107.1 Titers Interval 66.4 to 172.8	101.6 Titers Interval 62.4 to 165.3	—	—	—	—

SECONDARY outcome

Timeframe: At Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18

Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for M6+D7/D21, M18), which included all evaluable subjects for whom immunogenicity data were available and who complied with the criteria defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.

A seroconverted (SCR) subject was defined as a vaccinated subject who had either a pre-vaccination titer \<1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=50 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 21	0 Participants	3 Participants	0 Participants	3 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 42	—	—	15 Participants	23 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 7 Days	43 Participants	31 Participants	38 Participants	28 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 21 Days	46 Participants	35 Participants	42 Participants	35 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 12	16 Participants	29 Participants	19 Participants	31 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 18	26 Participants	18 Participants	28 Participants	20 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 21	19 Participants	24 Participants	23 Participants	29 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6	5 Participants	13 Participants	25 Participants	25 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 7 Days	43 Participants	36 Participants	29 Participants	27 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6	0 Participants	0 Participants	2 Participants	4 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 42	—	—	36 Participants	40 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 21 Days	46 Participants	38 Participants	41 Participants	34 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 12	33 Participants	35 Participants	32 Participants	37 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 18	11 Participants	15 Participants	9 Participants	7 Participants	—	—	—	—

SECONDARY outcome

Timeframe: At Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18

The seroconversion factor (SCF) was defined as the fold change in serum hemagglutination inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=66 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=63 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=61 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=64 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Indonesia, Month 6 + 7 Days	25.8 Fold Increase Interval 18.5 to 36.0	12.2 Fold Increase Interval 7.6 to 19.6	14.9 Fold Increase Interval 8.6 to 26.0	8.6 Fold Increase Interval 5.6 to 13.2	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Indonesia, Month 6	1.0 Fold Increase Interval 1.0 to 1.1	1.1 Fold Increase Interval 1.0 to 1.3	1.6 Fold Increase Interval 1.4 to 2.0	1.6 Fold Increase Interval 1.3 to 2.0	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Indonesia, Day 21	1.1 Fold Increase Interval 1.0 to 1.2	1.3 Fold Increase Interval 1.1 to 1.5	1.1 Fold Increase Interval 1.0 to 1.3	1.2 Fold Increase Interval 1.0 to 1.4	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Indonesia, Day 42	—	—	4.1 Fold Increase Interval 2.8 to 6.0	4.6 Fold Increase Interval 3.2 to 6.8	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Indonesia, Month 6 + 21 Days	52.5 Fold Increase Interval 36.7 to 75.0	18.5 Fold Increase Interval 11.9 to 28.8	45.3 Fold Increase Interval 29.9 to 68.5	17.5 Fold Increase Interval 11.2 to 27.4	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Indonesia, Month 12	2.9 Fold Increase Interval 2.1 to 4.0	8.9 Fold Increase Interval 5.8 to 13.6	5.5 Fold Increase Interval 3.7 to 8.3	11.6 Fold Increase Interval 7.4 to 18.2	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Indonesia, Month 18	5.7 Fold Increase Interval 3.7 to 8.5	3.7 Fold Increase Interval 2.5 to 5.7	6.0 Fold Increase Interval 4.0 to 9.0	4.3 Fold Increase Interval 2.7 to 6.7	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Vietnam, Day 21	3.0 Fold Increase Interval 2.2 to 4.0	4.0 Fold Increase Interval 2.8 to 5.8	5.7 Fold Increase Interval 3.8 to 8.5	5.4 Fold Increase Interval 3.8 to 7.9	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Vietnam, Day 42	—	—	50.3 Fold Increase Interval 34.8 to 72.7	40.8 Fold Increase Interval 27.5 to 60.5	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Vietnam, Month 6	1.7 Fold Increase Interval 1.4 to 2.1	2.4 Fold Increase Interval 1.8 to 3.2	6.4 Fold Increase Interval 4.5 to 8.9	6.0 Fold Increase Interval 4.3 to 8.5	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Vietnam, Month 6 + 7 Days	17.5 Fold Increase Interval 12.1 to 25.1	21.6 Fold Increase Interval 13.1 to 35.5	6.5 Fold Increase Interval 4.1 to 10.4	6.6 Fold Increase Interval 4.1 to 10.6	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Vietnam, Month 6 + 21 Days	34.7 Fold Increase Interval 23.9 to 50.5	32.3 Fold Increase Interval 19.8 to 52.7	18.3 Fold Increase Interval 11.6 to 28.9	11.0 Fold Increase Interval 6.8 to 17.9	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Vietnam, Month 12	9.6 Fold Increase Interval 6.3 to 14.7	14.3 Fold Increase Interval 9.6 to 21.4	19.0 Fold Increase Interval 12.9 to 28.1	22.5 Fold Increase Interval 14.5 to 34.9	—	—	—	—
Seroconversion Factor for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received the Booster Dose at Month 6 A/Vietnam, Month 18	2.1 Fold Increase Interval 1.5 to 3.1	2.7 Fold Increase Interval 1.7 to 4.2	1.5 Fold Increase Interval 1.1 to 2.2	1.5 Fold Increase Interval 0.9 to 2.3	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0, Day 21, Day 42, Month 6, Month 6+ 7 Days, Month 6+ 21 Days, Month 12 and Month 18

Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for M18), which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.

A seroprotected (SPR) subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=50 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 0	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 21	0 Participants	3 Participants	0 Participants	3 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 42	—	—	15 Participants	23 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6	0 Participants	0 Participants	2 Participants	4 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 7 Days	32 Participants	46 Participants	31 Participants	40 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 21 Days	37 Participants	48 Participants	37 Participants	45 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 12	16 Participants	29 Participants	19 Participants	31 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 18	26 Participants	18 Participants	30 Participants	21 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 0	0 Participants	0 Participants	2 Participants	1 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 21	19 Participants	24 Participants	24 Participants	29 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 42	—	—	36 Participants	40 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6	6 Participants	13 Participants	26 Participants	25 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 7 Days	39 Participants	49 Participants	38 Participants	42 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 21 Days	40 Participants	48 Participants	39 Participants	45 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 12	33 Participants	35 Participants	33 Participants	37 Participants	—	—	—	—
Number of Seroprotected Subjects for H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 18	21 Participants	24 Participants	30 Participants	24 Participants	—	—	—	—

SECONDARY outcome

Timeframe: At Month 12 + 7 Days, Month 12 + 21 Days and Month 18

Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for M18), which included all evaluable subjects for whom immunogenicity data/long term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.

Booster seroconversion (SCR) was defined as: For seronegative subjects at pre-booster (Month 12), antibody titer ≥ 1:40 at Month 12 + 7 days; For seropositive subjects at pre-booster (Month 12), antibody titer at Month 12 + 7 days ≥ 4 fold the pre-vaccination antibody titer at Month 12.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=50 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=51 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=40 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=43 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 18	39 Participants	34 Participants	37 Participants	34 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	41 Participants	49 Participants	36 Participants	43 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	38 Participants	43 Participants	34 Participants	39 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	43 Participants	46 Participants	34 Participants	38 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	44 Participants	50 Participants	37 Participants	43 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, A/Vietnam/1194/2004 and A/Indonesia/5/2005, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 18	30 Participants	33 Participants	34 Participants	29 Participants	—	—	—	—

SECONDARY outcome

Timeframe: At Month 12 + 7 Days and at Month 12 + 21 Days

Booster Factor (Seroconversion Factor booster) was defined as the fold change in H5N1 HI antibodies between the pre- and post-booster vaccination time-points (mean\[log10(POST/M12)\]). The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005, for groups who received the booster dose at Month 12.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=51 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=50 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=43 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=40 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	33.1 Fold Increase Interval 21.3 to 51.6	16.7 Fold Increase Interval 11.3 to 24.7	29.1 Fold Increase Interval 17.0 to 49.6	18.7 Fold Increase Interval 11.7 to 29.9	—	—	—	—
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	70.9 Fold Increase Interval 47.0 to 107.0	23.8 Fold Increase Interval 15.7 to 35.9	75.8 Fold Increase Interval 54.2 to 106.1	33.7 Fold Increase Interval 21.0 to 54.1	—	—	—	—
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	35.2 Fold Increase Interval 22.4 to 55.3	27.5 Fold Increase Interval 17.4 to 43.5	21.9 Fold Increase Interval 12.7 to 37.9	17.6 Fold Increase Interval 10.8 to 28.8	—	—	—	—
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	65.8 Fold Increase Interval 42.2 to 102.6	41.1 Fold Increase Interval 25.8 to 65.4	57.6 Fold Increase Interval 38.6 to 86.1	30.2 Fold Increase Interval 18.6 to 48.8	—	—	—	—

SECONDARY outcome

Timeframe: At Month 12 + 7 Days, Month 12 + 21 Days and at Month 18

Population: The analysis was performed on the ATP Cohort for persistence, which included all evaluable subjects for whom long term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.

Booster Factor (Seroconversion Factor booster) was defined as the fold change in H5N1 HI antibodies between the pre- and post-booster vaccination time-points (mean\[log10(POST/M12)\]). The 2 flu strains assessed were A/Vietnam/1194/2004 and A/Indonesia/05/2005, for groups who received the booster dose at Month 12.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=40 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=40 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	35.2 Fold Increase Interval 22.4 to 55.4	16.8 Fold Increase Interval 11.2 to 25.2	27.9 Fold Increase Interval 15.8 to 49.2	18.7 Fold Increase Interval 11.7 to 29.9	—	—	—	—
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	78.7 Fold Increase Interval 52.9 to 117.2	23.6 Fold Increase Interval 15.4 to 36.3	76.2 Fold Increase Interval 53.2 to 109.0	33.7 Fold Increase Interval 21.0 to 54.1	—	—	—	—
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 18	25.1 Fold Increase Interval 15.8 to 39.8	10.3 Fold Increase Interval 6.6 to 16.0	44.5 Fold Increase Interval 27.9 to 71.0	21.3 Fold Increase Interval 13.2 to 34.4	—	—	—	—
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 18	12.0 Fold Increase Interval 7.3 to 19.8	10.2 Fold Increase Interval 6.4 to 16.1	18.6 Fold Increase Interval 11.1 to 31.2	10.2 Fold Increase Interval 6.2 to 16.8	—	—	—	—
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	37.9 Fold Increase Interval 24.0 to 59.8	28.9 Fold Increase Interval 18.1 to 46.3	19.9 Fold Increase Interval 11.2 to 35.3	17.6 Fold Increase Interval 10.8 to 28.8	—	—	—	—
Booster Factor of H5N1 HI Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	73.6 Fold Increase Interval 47.9 to 113.3	43.1 Fold Increase Interval 26.6 to 69.6	55.7 Fold Increase Interval 36.4 to 85.3	30.2 Fold Increase Interval 18.6 to 48.8	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18

Population: This analysis was performed on the ATP Cohort for Immunogenicity and ATP Cohort for Persistence (only for M12, M18), which included all evaluable subjects for whom immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.

Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 All Doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The 2 flu strains assessed were A/Indonesia/05/2005 and A/Vietnam/1194/2004.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=41 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=42 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=36 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=35 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 All Doubles - A/Vietnam, Month 12	1316.68 cells/million T-cells Standard Deviation 1359.39	1431.92 cells/million T-cells Standard Deviation 1291.80	1506.94 cells/million T-cells Standard Deviation 1086.61	1220.87 cells/million T-cells Standard Deviation 2280.45	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 TNF-α - A/Vietnam, Month 6 + 7 Days	17.12 cells/million T-cells Standard Deviation 200.81	14.74 cells/million T-cells Standard Deviation 90.05	25.85 cells/million T-cells Standard Deviation 186.72	27.99 cells/million T-cells Standard Deviation 151.32	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 TNF-α - A/Vietnam, Month 6 + 21 Days	28.56 cells/million T-cells Standard Deviation 229.92	38.71 cells/million T-cells Standard Deviation 137.20	27.86 cells/million T-cells Standard Deviation 156.35	11.99 cells/million T-cells Standard Deviation 83.27	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 All Doubles - A/Vietnam, Month 6	600.07 cells/million T-cells Standard Deviation 901.78	807.14 cells/million T-cells Standard Deviation 806.63	896.67 cells/million T-cells Standard Deviation 627.38	1071.19 cells/million T-cells Standard Deviation 923.45	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 All Doubles - A/Vietnam, Month 6 + 21 Days	1619.46 cells/million T-cells Standard Deviation 1899.48	1531.69 cells/million T-cells Standard Deviation 1741.38	1489.30 cells/million T-cells Standard Deviation 1564.28	1953.30 cells/million T-cells Standard Deviation 2219.16	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 All Doubles - A/Indonesia, Month 12	1196.05 cells/million T-cells Standard Deviation 1279.60	1461.46 cells/million T-cells Standard Deviation 1972.69	1512.82 cells/million T-cells Standard Deviation 996.79	1243.41 cells/million T-cells Standard Deviation 1434.39	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 All Doubles - A/Indonesia, Month 18	1192.82 cells/million T-cells Standard Deviation 1000.13	1767.82 cells/million T-cells Standard Deviation 1194.85	1978.73 cells/million T-cells Standard Deviation 1138.17	1550.40 cells/million T-cells Standard Deviation 1557.30	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 All Doubles - A/Vietnam, Month 18	1194.69 cells/million T-cells Standard Deviation 1073.65	1790.56 cells/million T-cells Standard Deviation 1178.39	1676.20 cells/million T-cells Standard Deviation 1267.85	1560.54 cells/million T-cells Standard Deviation 1546.70	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 CD40L - A/Vietnam, Day 0	350.86 cells/million T-cells Standard Deviation 455.52	446.27 cells/million T-cells Standard Deviation 318.18	387.68 cells/million T-cells Standard Deviation 458.40	441.16 cells/million T-cells Standard Deviation 460.09	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 CD40L - A/Vietnam, Month 6	593.74 cells/million T-cells Standard Deviation 885.01	809.47 cells/million T-cells Standard Deviation 777.20	867.92 cells/million T-cells Standard Deviation 591.04	1046.99 cells/million T-cells Standard Deviation 893.54	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 CD40L- A/Vietnam, Month 18	1162.79 cells/million T-cells Standard Deviation 1043.15	1738.30 cells/million T-cells Standard Deviation 1140.59	1640.12 cells/million T-cells Standard Deviation 1252.01	1518.75 cells/million T-cells Standard Deviation 1489.22	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IL-2 - A/Vietnam, Day 0	262.64 cells/million T-cells Standard Deviation 339.55	264.51 cells/million T-cells Standard Deviation 249.40	230.40 cells/million T-cells Standard Deviation 360.46	289.83 cells/million T-cells Standard Deviation 385.44	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IL-2 - A/Vietnam, Month 6	450.20 cells/million T-cells Standard Deviation 815.29	601.02 cells/million T-cells Standard Deviation 736.05	648.07 cells/million T-cells Standard Deviation 584.83	719.07 cells/million T-cells Standard Deviation 763.89	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IL-2 - A/Vietnam, Month 6 + 7 Days	861.32 cells/million T-cells Standard Deviation 1997.52	890.90 cells/million T-cells Standard Deviation 1030.87	1390.30 cells/million T-cells Standard Deviation 1480.20	1147.31 cells/million T-cells Standard Deviation 980.42	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IL-2 - A/Vietnam, Month 6 + 21 Days	1238.06 cells/million T-cells Standard Deviation 1759.16	1036.73 cells/million T-cells Standard Deviation 1545.30	965.41 cells/million T-cells Standard Deviation 1302.89	1380.65 cells/million T-cells Standard Deviation 1761.07	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IL-2 - A/Vietnam, Month 12	1119.56 cells/million T-cells Standard Deviation 1261.18	1160.06 cells/million T-cells Standard Deviation 1049.95	1264.64 cells/million T-cells Standard Deviation 1008.46	999.23 cells/million T-cells Standard Deviation 2005.29	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IFN-γ - A/Vietnam, Month 6 + 7 Days	632.73 cells/million T-cells Standard Deviation 848.00	683.35 cells/million T-cells Standard Deviation 702.66	826.27 cells/million T-cells Standard Deviation 856.63	887.74 cells/million T-cells Standard Deviation 412.30	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IFN-γ - A/Indonesia, Month 12	615.47 cells/million T-cells Standard Deviation 624.58	829.05 cells/million T-cells Standard Deviation 903.32	752.50 cells/million T-cells Standard Deviation 525.81	746.33 cells/million T-cells Standard Deviation 727.94	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 TNF-α - A/Indonesia, Month 12	914.94 cells/million T-cells Standard Deviation 1053.34	1125.16 cells/million T-cells Standard Deviation 1559.54	1235.28 cells/million T-cells Standard Deviation 813.44	1148.53 cells/million T-cells Standard Deviation 1208.96	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 TNF-α - A/Vietnam, Month 12	970.90 cells/million T-cells Standard Deviation 1091.23	1047.93 cells/million T-cells Standard Deviation 978.11	1238.05 cells/million T-cells Standard Deviation 858.40	1096.87 cells/million T-cells Standard Deviation 1906.75	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 TNF-α - A/Indonesia, Month 18	922.42 cells/million T-cells Standard Deviation 794.83	1318.59 cells/million T-cells Standard Deviation 923.86	1647.61 cells/million T-cells Standard Deviation 927.11	1224.50 cells/million T-cells Standard Deviation 1267.20	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 All Doubles - A/Vietnam, Month 18	33.20 cells/million T-cells Standard Deviation 623.81	12.14 cells/million T-cells Standard Deviation 907.62	29.83 cells/million T-cells Standard Deviation 673.80	11.17 cells/million T-cells Standard Deviation 676.65	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 CD40L - A/Vietnam, Day 0	7.17 cells/million T-cells Standard Deviation 84.29	4.74 cells/million T-cells Standard Deviation 71.68	5.49 cells/million T-cells Standard Deviation 39.03	6.15 cells/million T-cells Standard Deviation 165.75	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 CD40L - A/Vietnam, Month 6	3.12 cells/million T-cells Standard Deviation 35.61	7.18 cells/million T-cells Standard Deviation 39.67	5.01 cells/million T-cells Standard Deviation 69.22	4.81 cells/million T-cells Standard Deviation 49.19	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 CD40L - A/Vietnam, Month 6 + 21 Days	2.11 cells/million T-cells Standard Deviation 22.77	4.88 cells/million T-cells Standard Deviation 37.26	3.78 cells/million T-cells Standard Deviation 33.23	3.21 cells/million T-cells Standard Deviation 30.61	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 CD40L - A/Vietnam, Month 18	5.71 cells/million T-cells Standard Deviation 53.55	2.75 cells/million T-cells Standard Deviation 96.74	4.14 cells/million T-cells Standard Deviation 95.17	3.07 cells/million T-cells Standard Deviation 40.00	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IL-2 - A/Vietnam, Day 0	36.92 cells/million T-cells Standard Deviation 229.00	14.67 cells/million T-cells Standard Deviation 100.62	16.98 cells/million T-cells Standard Deviation 130.69	27.00 cells/million T-cells Standard Deviation 258.14	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IL-2 - A/Vietnam, Month 6	12.84 cells/million T-cells Standard Deviation 129.21	12.58 cells/million T-cells Standard Deviation 239.74	22.68 cells/million T-cells Standard Deviation 113.81	25.91 cells/million T-cells Standard Deviation 102.37	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IL-2 - A/Vietnam, Month 6 + 7 Days	16.03 cells/million T-cells Standard Deviation 218.16	17.04 cells/million T-cells Standard Deviation 92.98	32.94 cells/million T-cells Standard Deviation 154.53	26.46 cells/million T-cells Standard Deviation 113.81	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IL-2 - A/Vietnam, Month 6 + 21 Days	31.00 cells/million T-cells Standard Deviation 185.96	28.04 cells/million T-cells Standard Deviation 156.16	22.75 cells/million T-cells Standard Deviation 138.13	13.48 cells/million T-cells Standard Deviation 93.72	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IL-2 - A/Indonesia, Month 12	40.26 cells/million T-cells Standard Deviation 1211.36	27.79 cells/million T-cells Standard Deviation 1135.75	48.91 cells/million T-cells Standard Deviation 1897.48	28.61 cells/million T-cells Standard Deviation 1566.57	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IL-2 - A/Vietnam, Month 18	32.16 cells/million T-cells Standard Deviation 615.73	11.75 cells/million T-cells Standard Deviation 902.78	26.63 cells/million T-cells Standard Deviation 674.63	9.50 cells/million T-cells Standard Deviation 678.33	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IFN-γ - A/Vietnam, Day 0	29.70 cells/million T-cells Standard Deviation 347.16	14.50 cells/million T-cells Standard Deviation 125.14	24.17 cells/million T-cells Standard Deviation 183.45	23.68 cells/million T-cells Standard Deviation 347.01	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IFN-γ - A/Vietnam, Month 6	9.15 cells/million T-cells Standard Deviation 195.76	15.10 cells/million T-cells Standard Deviation 164.89	25.09 cells/million T-cells Standard Deviation 269.60	10.92 cells/million T-cells Standard Deviation 133.43	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IFN-γ - A/Vietnam, Month 6 + 7 days	17.52 cells/million T-cells Standard Deviation 252.30	6.54 cells/million T-cells Standard Deviation 65.11	6.15 cells/million T-cells Standard Deviation 190.69	12.90 cells/million T-cells Standard Deviation 96.83	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IFN-γ - A/Vietnam, Month 12	4.44 cells/million T-cells Standard Deviation 305.15	4.24 cells/million T-cells Standard Deviation 133.39	10.21 cells/million T-cells Standard Deviation 83.42	4.42 cells/million T-cells Standard Deviation 56.81	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IFN-γ - A/Indonesia, Month 18	4.74 cells/million T-cells Standard Deviation 91.61	4.33 cells/million T-cells Standard Deviation 111.98	4.61 cells/million T-cells Standard Deviation 83.81	3.73 cells/million T-cells Standard Deviation 97.93	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 TNF-α - A/Vietnam, Day 0	25.46 cells/million T-cells Standard Deviation 308.45	14.67 cells/million T-cells Standard Deviation 92.23	22.21 cells/million T-cells Standard Deviation 183.41	35.35 cells/million T-cells Standard Deviation 219.77	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 All Doubles - A/Vietnam, Day 0	412.03 cells/million T-cells Standard Deviation 487.53	467.30 cells/million T-cells Standard Deviation 333.87	395.60 cells/million T-cells Standard Deviation 477.64	469.25 cells/million T-cells Standard Deviation 470.89	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 All Doubles - A/Vietnam, Month 6 + 7 Days	1120.95 cells/million T-cells Standard Deviation 2182.54	1369.15 cells/million T-cells Standard Deviation 1224.75	1914.50 cells/million T-cells Standard Deviation 1757.90	1769.33 cells/million T-cells Standard Deviation 1024.50	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 CD40L - A/Vietnam, Month 6 + 7 Days	1084.46 cells/million T-cells Standard Deviation 2123.12	1298.95 cells/million T-cells Standard Deviation 1153.28	1818.39 cells/million T-cells Standard Deviation 1603.64	1717.69 cells/million T-cells Standard Deviation 990.51	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 CD40L - A/Vietnam, Month 6 + 21 Days	1588.60 cells/million T-cells Standard Deviation 1855.12	1487.73 cells/million T-cells Standard Deviation 1663.98	1480.21 cells/million T-cells Standard Deviation 1520.92	1880.07 cells/million T-cells Standard Deviation 2151.87	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 CD40L - A/Indonesia, Month 12	1183.85 cells/million T-cells Standard Deviation 1255.59	1448.44 cells/million T-cells Standard Deviation 1973.98	1505.73 cells/million T-cells Standard Deviation 985.99	1221.20 cells/million T-cells Standard Deviation 1371.18	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 CD40L - A/Vietnam, Month 12	1238.24 cells/million T-cells Standard Deviation 1362.58	1390.02 cells/million T-cells Standard Deviation 1288.92	1474.26 cells/million T-cells Standard Deviation 1073.10	1152.29 cells/million T-cells Standard Deviation 2263.92	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 CD40L - A/Indonesia, Month 18	1172.36 cells/million T-cells Standard Deviation 985.13	1747.96 cells/million T-cells Standard Deviation 1151.98	1975.69 cells/million T-cells Standard Deviation 1126.07	1522.12 cells/million T-cells Standard Deviation 1553.48	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IL-2 - A/Indonesia, Month 12	1001.88 cells/million T-cells Standard Deviation 1156.16	1169.25 cells/million T-cells Standard Deviation 1630.99	1278.49 cells/million T-cells Standard Deviation 908.04	1041.21 cells/million T-cells Standard Deviation 1250.37	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IL-2 - A/Indonesia, Month 18	999.22 cells/million T-cells Standard Deviation 844.48	1412.43 cells/million T-cells Standard Deviation 986.25	1480.68 cells/million T-cells Standard Deviation 1040.08	1248.66 cells/million T-cells Standard Deviation 1383.46	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IL-2- A/Vietnam, Month 18	1011.14 cells/million T-cells Standard Deviation 921.27	1487.16 cells/million T-cells Standard Deviation 1006.20	1434.59 cells/million T-cells Standard Deviation 1156.89	1140.29 cells/million T-cells Standard Deviation 1374.45	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IFN-γ - A/Vietnam, Day 0	303.97 cells/million T-cells Standard Deviation 403.90	267.88 cells/million T-cells Standard Deviation 316.20	275.09 cells/million T-cells Standard Deviation 299.79	331.35 cells/million T-cells Standard Deviation 379.46	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IFN-γ - A/Vietnam, Month 6	309.94 cells/million T-cells Standard Deviation 596.66	486.23 cells/million T-cells Standard Deviation 524.58	406.50 cells/million T-cells Standard Deviation 364.57	543.11 cells/million T-cells Standard Deviation 607.67	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IFN-γ - A/Vietnam, Month 6 + 21 Days	769.33 cells/million T-cells Standard Deviation 858.31	831.31 cells/million T-cells Standard Deviation 964.67	712.10 cells/million T-cells Standard Deviation 806.47	908.75 cells/million T-cells Standard Deviation 952.74	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IFN-γ - A/Vietnam, Month 12	751.16 cells/million T-cells Standard Deviation 604.70	851.71 cells/million T-cells Standard Deviation 727.68	817.48 cells/million T-cells Standard Deviation 568.54	832.49 cells/million T-cells Standard Deviation 1138.08	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IFN-γ - A/Indonesia, Month 18	657.19 cells/million T-cells Standard Deviation 622.98	972.81 cells/million T-cells Standard Deviation 1026.12	1017.82 cells/million T-cells Standard Deviation 655.54	883.75 cells/million T-cells Standard Deviation 969.20	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 IFN-γ - A/Vietnam, Month 18	698.55 cells/million T-cells Standard Deviation 804.64	1018.23 cells/million T-cells Standard Deviation 959.34	1066.89 cells/million T-cells Standard Deviation 845.76	949.06 cells/million T-cells Standard Deviation 949.59	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 TNF-α - A/Vietnam, Day 0	213.17 cells/million T-cells Standard Deviation 314.89	290.55 cells/million T-cells Standard Deviation 244.57	248.53 cells/million T-cells Standard Deviation 334.40	262.12 cells/million T-cells Standard Deviation 309.11	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 TNF-α - A/Vietnam, Month 6	389.55 cells/million T-cells Standard Deviation 823.34	459.89 cells/million T-cells Standard Deviation 709.54	501.89 cells/million T-cells Standard Deviation 496.82	684.19 cells/million T-cells Standard Deviation 700.61	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 TNF-α - A/Vietnam, Month 6 + 7 Days	605.80 cells/million T-cells Standard Deviation 1282.37	700.69 cells/million T-cells Standard Deviation 893.07	1160.60 cells/million T-cells Standard Deviation 1524.45	972.71 cells/million T-cells Standard Deviation 668.12	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 TNF-α - A/Vietnam, Month 6 + 21 Days	880.12 cells/million T-cells Standard Deviation 1327.15	971.44 cells/million T-cells Standard Deviation 1419.68	881.65 cells/million T-cells Standard Deviation 1218.69	1227.63 cells/million T-cells Standard Deviation 1871.42	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD4 TNF-α - A/Vietnam, Month 18	877.90 cells/million T-cells Standard Deviation 810.80	1314.99 cells/million T-cells Standard Deviation 846.99	1232.41 cells/million T-cells Standard Deviation 1079.43	1147.21 cells/million T-cells Standard Deviation 1402.58	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 All Doubles - A/Vietnam, Day 0	67.13 cells/million T-cells Standard Deviation 366.43	26.91 cells/million T-cells Standard Deviation 128.98	30.44 cells/million T-cells Standard Deviation 219.02	45.07 cells/million T-cells Standard Deviation 377.44	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 All Doubles - A/Vietnam, Month 6	20.86 cells/million T-cells Standard Deviation 222.56	18.86 cells/million T-cells Standard Deviation 271.65	37.69 cells/million T-cells Standard Deviation 271.61	40.43 cells/million T-cells Standard Deviation 148.42	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 All Doubles - A/Vietnam, Month 6 + 7 Days	23.01 cells/million T-cells Standard Deviation 290.71	27.73 cells/million T-cells Standard Deviation 93.80	38.78 cells/million T-cells Standard Deviation 211.71	32.56 cells/million T-cells Standard Deviation 150.48	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 All Doubles - A/Vietnam, Month 6 + 21 Days	29.21 cells/million T-cells Standard Deviation 281.87	52.59 cells/million T-cells Standard Deviation 159.49	36.47 cells/million T-cells Standard Deviation 171.22	16.93 cells/million T-cells Standard Deviation 105.56	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 All Doubles - A/Indonesia, Month 12	47.78 cells/million T-cells Standard Deviation 1206.89	31.69 cells/million T-cells Standard Deviation 1136.66	64.08 cells/million T-cells Standard Deviation 1893.94	36.18 cells/million T-cells Standard Deviation 1567.28	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 All Doubles - A/Vietnam, Month 12	15.04 cells/million T-cells Standard Deviation 544.79	21.08 cells/million T-cells Standard Deviation 635.65	37.32 cells/million T-cells Standard Deviation 744.75	14.09 cells/million T-cells Standard Deviation 771.65	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 All Doubles - A/Indonesia, Month 18	48.27 cells/million T-cells Standard Deviation 1109.56	24.19 cells/million T-cells Standard Deviation 1162.30	82.90 cells/million T-cells Standard Deviation 1266.82	34.07 cells/million T-cells Standard Deviation 1414.34	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 CD40L - A/Vietnam, Month 6 + 7 Days	6.26 cells/million T-cells Standard Deviation 71.82	3.55 cells/million T-cells Standard Deviation 30.06	6.28 cells/million T-cells Standard Deviation 34.99	5.92 cells/million T-cells Standard Deviation 45.82	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 CD40L - A/Indonesia, Month 12	3.92 cells/million T-cells Standard Deviation 58.33	5.74 cells/million T-cells Standard Deviation 93.30	9.05 cells/million T-cells Standard Deviation 186.92	7.74 cells/million T-cells Standard Deviation 144.04	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 CD40L - A/Vietnam, Month 12	2.27 cells/million T-cells Standard Deviation 33.81	3.40 cells/million T-cells Standard Deviation 67.73	5.10 cells/million T-cells Standard Deviation 65.14	3.35 cells/million T-cells Standard Deviation 47.52	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 CD40L - A/Indonesia, Month 18	5.88 cells/million T-cells Standard Deviation 71.14	5.23 cells/million T-cells Standard Deviation 269.38	5.25 cells/million T-cells Standard Deviation 71.46	3.66 cells/million T-cells Standard Deviation 56.08	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IL-2 - A/Vietnam, Month 12	14.98 cells/million T-cells Standard Deviation 532.13	21.52 cells/million T-cells Standard Deviation 631.86	31.94 cells/million T-cells Standard Deviation 746.85	13.31 cells/million T-cells Standard Deviation 773.02	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IL-2 - A/Indonesia, Month 18	43.26 cells/million T-cells Standard Deviation 1110.98	19.50 cells/million T-cells Standard Deviation 1164.40	66.29 cells/million T-cells Standard Deviation 1268.66	33.60 cells/million T-cells Standard Deviation 1414.79	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IFN-γ - A/Vietnam, Month 6 + 21 Days	9.86 cells/million T-cells Standard Deviation 272.26	16.87 cells/million T-cells Standard Deviation 111.49	15.44 cells/million T-cells Standard Deviation 132.81	11.37 cells/million T-cells Standard Deviation 82.16	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IFN-γ - A/Indonesia, Month 12	3.05 cells/million T-cells Standard Deviation 131.52	4.05 cells/million T-cells Standard Deviation 147.20	4.11 cells/million T-cells Standard Deviation 75.97	2.83 cells/million T-cells Standard Deviation 38.52	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 IFN-γ - A/Vietnam, Month 18	5.73 cells/million T-cells Standard Deviation 64.14	3.55 cells/million T-cells Standard Deviation 138.59	5.22 cells/million T-cells Standard Deviation 95.47	3.15 cells/million T-cells Standard Deviation 107.32	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 TNF-α - A/Vietnam, Month 6	11.60 cells/million T-cells Standard Deviation 192.99	17.44 cells/million T-cells Standard Deviation 260.42	21.86 cells/million T-cells Standard Deviation 254.39	20.44 cells/million T-cells Standard Deviation 140.65	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 TNF-α - A/Indonesia, Month 12	46.49 cells/million T-cells Standard Deviation 1154.66	27.72 cells/million T-cells Standard Deviation 1030.52	57.62 cells/million T-cells Standard Deviation 1753.76	31.65 cells/million T-cells Standard Deviation 1425.49	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 TNF-α - A/Vietnam, Month 12	13.46 cells/million T-cells Standard Deviation 423.36	18.89 cells/million T-cells Standard Deviation 579.22	35.19 cells/million T-cells Standard Deviation 698.32	12.30 cells/million T-cells Standard Deviation 725.71	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 TNF-α - A/Indonesia, Month 18	45.67 cells/million T-cells Standard Deviation 1033.79	22.55 cells/million T-cells Standard Deviation 1002.19	70.09 cells/million T-cells Standard Deviation 1200.29	34.37 cells/million T-cells Standard Deviation 1369.22	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 6 CD8 TNF-α - A/Vietnam, Month 18	31.41 cells/million T-cells Standard Deviation 580.62	12.96 cells/million T-cells Standard Deviation 816.63	21.36 cells/million T-cells Standard Deviation 614.44	9.31 cells/million T-cells Standard Deviation 642.97	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days and Month 18

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=51 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=43 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 All Doubles - A/Vietnam, Day 0	560.41 cells/million T-cells Standard Deviation 427.07	529.20 cells/million T-cells Standard Deviation 549.34	542.86 cells/million T-cells Standard Deviation 488.28	771.60 cells/million T-cells Standard Deviation 788.54	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 All Doubles - A/Vietnam, Month 6	1296.63 cells/million T-cells Standard Deviation 839.72	931.49 cells/million T-cells Standard Deviation 717.72	1714.23 cells/million T-cells Standard Deviation 837.39	1601.31 cells/million T-cells Standard Deviation 1020.97	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 All Doubles - A/Indonesia, Month 12	1379.04 cells/million T-cells Standard Deviation 701.03	1254.05 cells/million T-cells Standard Deviation 835.74	1690.38 cells/million T-cells Standard Deviation 1135.04	1534.37 cells/million T-cells Standard Deviation 1256.20	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 All Doubles - A/Indonesia, Month 12 + 7 Days	1979.02 cells/million T-cells Standard Deviation 1644.97	1763.05 cells/million T-cells Standard Deviation 1266.55	3030.85 cells/million T-cells Standard Deviation 1974.08	3202.67 cells/million T-cells Standard Deviation 7114.42	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 All Doubles - A/Vietnam, Month 12 + 7 days	2278.65 cells/million T-cells Standard Deviation 2822.40	1856.17 cells/million T-cells Standard Deviation 1517.33	2953.57 cells/million T-cells Standard Deviation 2725.45	3502.70 cells/million T-cells Standard Deviation 19908.39	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 All Doubles - A/Indonesia, Month 18	2003.28 cells/million T-cells Standard Deviation 964.77	1530.61 cells/million T-cells Standard Deviation 1228.44	2975.66 cells/million T-cells Standard Deviation 1696.72	2458.61 cells/million T-cells Standard Deviation 1829.69	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 CD40L - A/Vietnam, Month 12 + 7 Days	2179.65 cells/million T-cells Standard Deviation 2615.03	1781.72 cells/million T-cells Standard Deviation 1287.53	2842.20 cells/million T-cells Standard Deviation 2607.80	3365.20 cells/million T-cells Standard Deviation 18999.95	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IL-2 - A/Indonesia, Month 12	1149.50 cells/million T-cells Standard Deviation 571.65	1065.33 cells/million T-cells Standard Deviation 661.19	1517.94 cells/million T-cells Standard Deviation 1028.90	1293.00 cells/million T-cells Standard Deviation 1103.73	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IL-2 - A/Vietnam, Month 12 + 7 Days	1897.17 cells/million T-cells Standard Deviation 2415.04	1533.21 cells/million T-cells Standard Deviation 1397.88	2477.58 cells/million T-cells Standard Deviation 2347.38	2942.81 cells/million T-cells Standard Deviation 17299.39	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IFN-γ - A/Vietnam, Day 0	410.28 cells/million T-cells Standard Deviation 363.50	336.74 cells/million T-cells Standard Deviation 443.20	379.98 cells/million T-cells Standard Deviation 364.14	476.66 cells/million T-cells Standard Deviation 687.60	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IFN-γ - A/Indonesia, Month 12	716.74 cells/million T-cells Standard Deviation 400.83	609.84 cells/million T-cells Standard Deviation 578.82	832.27 cells/million T-cells Standard Deviation 746.45	794.44 cells/million T-cells Standard Deviation 765.51	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IFN-γ - A/Vietnam, Month 12 + 7 Days	1131.19 cells/million T-cells Standard Deviation 1352.73	892.51 cells/million T-cells Standard Deviation 905.48	1335.77 cells/million T-cells Standard Deviation 1104.69	1635.21 cells/million T-cells Standard Deviation 7167.21	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IFN-γ - A/Indonesia, Month 12 + 21 Days	1245.91 cells/million T-cells Standard Deviation 936.91	948.13 cells/million T-cells Standard Deviation 1366.34	1540.77 cells/million T-cells Standard Deviation 1136.61	1662.38 cells/million T-cells Standard Deviation 1310.77	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IFN-γ - A/Vietnam, Month 18	1309.65 cells/million T-cells Standard Deviation 1177.92	901.99 cells/million T-cells Standard Deviation 1416.15	1418.76 cells/million T-cells Standard Deviation 1038.94	1284.53 cells/million T-cells Standard Deviation 1281.98	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 TNF-α - A/Vietnam, Day 0	355.17 cells/million T-cells Standard Deviation 302.08	287.10 cells/million T-cells Standard Deviation 423.56	341.11 cells/million T-cells Standard Deviation 356.99	512.64 cells/million T-cells Standard Deviation 572.95	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 TNF-α - A/Vietnam, Month 6	886.97 cells/million T-cells Standard Deviation 662.75	629.87 cells/million T-cells Standard Deviation 556.20	1187.24 cells/million T-cells Standard Deviation 710.18	1180.29 cells/million T-cells Standard Deviation 829.76	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 TNF-α - A/Indonesia, Month 12	1020.53 cells/million T-cells Standard Deviation 642.48	896.53 cells/million T-cells Standard Deviation 690.42	1251.38 cells/million T-cells Standard Deviation 970.03	995.80 cells/million T-cells Standard Deviation 1066.30	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 TNF-α - A/Vietnam, Month 12	886.76 cells/million T-cells Standard Deviation 457.39	673.80 cells/million T-cells Standard Deviation 651.52	790.01 cells/million T-cells Standard Deviation 938.28	903.64 cells/million T-cells Standard Deviation 2220.85	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 TNF-α - A/Indonesia, Month 12 + 7 Days	1198.25 cells/million T-cells Standard Deviation 1200.42	1217.50 cells/million T-cells Standard Deviation 971.57	2108.88 cells/million T-cells Standard Deviation 1380.62	2379.07 cells/million T-cells Standard Deviation 5801.63	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 TNF-α - A/Vietnam, Month 12 + 7 Days	1289.39 cells/million T-cells Standard Deviation 2162.71	1136.90 cells/million T-cells Standard Deviation 1164.93	1997.48 cells/million T-cells Standard Deviation 1725.20	2466.32 cells/million T-cells Standard Deviation 16740.25	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 TNF-α - A/Indonesia, Month 12 + 21 Days	2047.96 cells/million T-cells Standard Deviation 1439.33	1515.97 cells/million T-cells Standard Deviation 1751.14	2800.66 cells/million T-cells Standard Deviation 2480.69	2510.61 cells/million T-cells Standard Deviation 2450.88	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 TNF-α - A/Vietnam, Month 12 + 21 Days	1833.81 cells/million T-cells Standard Deviation 2015.18	1428.02 cells/million T-cells Standard Deviation 1030.82	2373.80 cells/million T-cells Standard Deviation 2542.38	2571.60 cells/million T-cells Standard Deviation 3441.06	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 TNF-α - A/Indonesia, Month 18	1461.90 cells/million T-cells Standard Deviation 863.23	1009.39 cells/million T-cells Standard Deviation 1077.18	2445.88 cells/million T-cells Standard Deviation 1505.10	1979.21 cells/million T-cells Standard Deviation 1590.60	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 TNF-α - A/Vietnam, Month 18	1499.43 cells/million T-cells Standard Deviation 1302.01	1250.85 cells/million T-cells Standard Deviation 1843.92	2269.35 cells/million T-cells Standard Deviation 1494.81	1914.16 cells/million T-cells Standard Deviation 2270.93	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 All Doubles - A/Vietnam, Day 0	33.23 cells/million T-cells Standard Deviation 473.07	30.79 cells/million T-cells Standard Deviation 332.90	18.67 cells/million T-cells Standard Deviation 297.54	21.71 cells/million T-cells Standard Deviation 163.41	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 All Doubles - A/Vietnam, Month 6	56.22 cells/million T-cells Standard Deviation 359.78	60.15 cells/million T-cells Standard Deviation 348.65	31.83 cells/million T-cells Standard Deviation 296.96	34.66 cells/million T-cells Standard Deviation 208.62	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 All Doubles - A/Indonesia, Month 12	41.20 cells/million T-cells Standard Deviation 285.40	19.96 cells/million T-cells Standard Deviation 258.08	33.27 cells/million T-cells Standard Deviation 237.99	34.16 cells/million T-cells Standard Deviation 449.53	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 All Doubles - A/Vietnam, Month 12	14.72 cells/million T-cells Standard Deviation 293.17	13.96 cells/million T-cells Standard Deviation 149.10	8.90 cells/million T-cells Standard Deviation 107.93	30.14 cells/million T-cells Standard Deviation 365.90	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 All Doubles - A/Indonesia, Month 12 + 7 Days	68.32 cells/million T-cells Standard Deviation 385.82	48.09 cells/million T-cells Standard Deviation 292.33	41.66 cells/million T-cells Standard Deviation 276.01	57.43 cells/million T-cells Standard Deviation 369.42	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 All Doubles - A/Vietnam, Month 12 + 7 Days	18.73 cells/million T-cells Standard Deviation 398.89	23.11 cells/million T-cells Standard Deviation 409.70	9.04 cells/million T-cells Standard Deviation 325.93	62.81 cells/million T-cells Standard Deviation 426.34	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 All Doubles - A/Indonesia, Month 12 + 21 Days	59.21 cells/million T-cells Standard Deviation 402.04	22.21 cells/million T-cells Standard Deviation 196.85	42.28 cells/million T-cells Standard Deviation 213.86	60.95 cells/million T-cells Standard Deviation 301.71	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 All Doubles - A/Vietnam, Month 12 + 21 Days	16.35 cells/million T-cells Standard Deviation 341.81	10.06 cells/million T-cells Standard Deviation 260.79	16.58 cells/million T-cells Standard Deviation 227.02	51.01 cells/million T-cells Standard Deviation 320.71	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 All Doubles - A/Indonesia, Month 18	45.87 cells/million T-cells Standard Deviation 268.24	36.98 cells/million T-cells Standard Deviation 349.38	29.12 cells/million T-cells Standard Deviation 194.72	36.73 cells/million T-cells Standard Deviation 391.36	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 All Doubles - A/Vietnam, Month 18	27.14 cells/million T-cells Standard Deviation 378.73	17.52 cells/million T-cells Standard Deviation 231.65	26.49 cells/million T-cells Standard Deviation 396.90	17.79 cells/million T-cells Standard Deviation 189.35	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 CD40L - A/Vietnam, Day 0	3.05 cells/million T-cells Standard Deviation 54.73	3.22 cells/million T-cells Standard Deviation 55.84	2.48 cells/million T-cells Standard Deviation 130.89	2.79 cells/million T-cells Standard Deviation 19.72	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 CD40L - A/Vietnam, Month 6	2.59 cells/million T-cells Standard Deviation 24.33	3.07 cells/million T-cells Standard Deviation 55.80	3.00 cells/million T-cells Standard Deviation 101.52	1.51 cells/million T-cells Standard Deviation 20.14	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 CD40L - A/Indonesia, Month 12	2.09 cells/million T-cells Standard Deviation 28.38	3.66 cells/million T-cells Standard Deviation 26.90	4.44 cells/million T-cells Standard Deviation 40.48	4.48 cells/million T-cells Standard Deviation 83.08	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 CD40L - A/Vietnam, Month 12	2.33 cells/million T-cells Standard Deviation 34.71	2.47 cells/million T-cells Standard Deviation 32.62	2.16 cells/million T-cells Standard Deviation 52.15	2.87 cells/million T-cells Standard Deviation 40.66	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 CD40L - A/Indonesia, Month 12 + 7 Days	8.21 cells/million T-cells Standard Deviation 51.25	7.68 cells/million T-cells Standard Deviation 119.95	13.23 cells/million T-cells Standard Deviation 99.16	7.76 cells/million T-cells Standard Deviation 99.48	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 CD40L - A/Vietnam, Month 12 + 7 Days	4.40 cells/million T-cells Standard Deviation 30.87	2.90 cells/million T-cells Standard Deviation 183.17	2.90 cells/million T-cells Standard Deviation 39.63	10.59 cells/million T-cells Standard Deviation 52.19	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 CD40L - A/Indonesia, Month 12 + 21 Days	5.43 cells/million T-cells Standard Deviation 73.31	5.98 cells/million T-cells Standard Deviation 61.91	8.29 cells/million T-cells Standard Deviation 57.18	7.45 cells/million T-cells Standard Deviation 96.27	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 CD40L - A/Vietnam, Month 12 + 21 Days	3.96 cells/million T-cells Standard Deviation 67.70	2.44 cells/million T-cells Standard Deviation 92.98	3.11 cells/million T-cells Standard Deviation 32.25	3.70 cells/million T-cells Standard Deviation 34.54	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 CD40L - A/Indonesia, Month 18	3.52 cells/million T-cells Standard Deviation 49.19	4.22 cells/million T-cells Standard Deviation 56.87	2.45 cells/million T-cells Standard Deviation 37.14	2.75 cells/million T-cells Standard Deviation 36.15	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 CD40L - A/Vietnam, Month 18	4.32 cells/million T-cells Standard Deviation 59.02	3.84 cells/million T-cells Standard Deviation 75.59	4.78 cells/million T-cells Standard Deviation 62.03	2.09 cells/million T-cells Standard Deviation 59.01	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IL-2 - A/Vietnam, Day 0	18.34 cells/million T-cells Standard Deviation 169.79	22.25 cells/million T-cells Standard Deviation 202.40	10.40 cells/million T-cells Standard Deviation 167.00	15.03 cells/million T-cells Standard Deviation 86.58	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IL-2 - A/Vietnam, Month 6	24.13 cells/million T-cells Standard Deviation 246.71	30.85 cells/million T-cells Standard Deviation 186.03	16.53 cells/million T-cells Standard Deviation 173.90	19.63 cells/million T-cells Standard Deviation 145.48	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IL-2 - A/Indonesia, Month 12	29.84 cells/million T-cells Standard Deviation 250.29	18.29 cells/million T-cells Standard Deviation 246.48	17.80 cells/million T-cells Standard Deviation 236.04	28.56 cells/million T-cells Standard Deviation 430.21	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IL-2 - A/Vietnam, Month 12	9.12 cells/million T-cells Standard Deviation 276.25	12.06 cells/million T-cells Standard Deviation 148.06	8.22 cells/million T-cells Standard Deviation 80.21	35.92 cells/million T-cells Standard Deviation 362.09	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IL-2 - A/Indonesia, Month 12 + 7 Days	55.96 cells/million T-cells Standard Deviation 393.80	36.88 cells/million T-cells Standard Deviation 268.94	28.07 cells/million T-cells Standard Deviation 261.31	61.72 cells/million T-cells Standard Deviation 318.59	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IL-2 - A/Vietnam, Month 12 + 7 Days	20.48 cells/million T-cells Standard Deviation 385.51	23.40 cells/million T-cells Standard Deviation 399.09	8.29 cells/million T-cells Standard Deviation 278.07	52.32 cells/million T-cells Standard Deviation 392.40	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IL-2 - A/Indonesia, Month 12 + 21 Days	62.99 cells/million T-cells Standard Deviation 387.92	19.97 cells/million T-cells Standard Deviation 198.10	31.51 cells/million T-cells Standard Deviation 216.34	43.10 cells/million T-cells Standard Deviation 277.22	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IL-2 - A/Vietnam, Month 12 + 21 Days	12.52 cells/million T-cells Standard Deviation 278.19	8.59 cells/million T-cells Standard Deviation 207.18	14.20 cells/million T-cells Standard Deviation 208.85	47.66 cells/million T-cells Standard Deviation 280.88	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IL-2 - A/Indonesia, Month 18	45.30 cells/million T-cells Standard Deviation 266.64	31.29 cells/million T-cells Standard Deviation 340.10	19.06 cells/million T-cells Standard Deviation 157.42	31.56 cells/million T-cells Standard Deviation 385.23	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IL-2 - A/Vietnam, Month 18	15.35 cells/million T-cells Standard Deviation 281.28	15.08 cells/million T-cells Standard Deviation 211.25	14.48 cells/million T-cells Standard Deviation 250.77	21.78 cells/million T-cells Standard Deviation 153.80	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IFN-γ - A/Vietnam, Day 0	38.69 cells/million T-cells Standard Deviation 468.52	22.01 cells/million T-cells Standard Deviation 312.45	16.63 cells/million T-cells Standard Deviation 273.01	24.90 cells/million T-cells Standard Deviation 165.67	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IFN-γ - A/Vietnam, Month 6	31.09 cells/million T-cells Standard Deviation 359.03	42.77 cells/million T-cells Standard Deviation 334.23	24.28 cells/million T-cells Standard Deviation 290.45	30.08 cells/million T-cells Standard Deviation 200.12	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IFN-γ - A/Indonesia, Month 12	10.22 cells/million T-cells Standard Deviation 195.65	6.58 cells/million T-cells Standard Deviation 85.93	19.40 cells/million T-cells Standard Deviation 172.59	13.70 cells/million T-cells Standard Deviation 342.47	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IFN-γ - A/Vietnam, Month 12	5.79 cells/million T-cells Standard Deviation 214.35	7.07 cells/million T-cells Standard Deviation 174.18	4.31 cells/million T-cells Standard Deviation 101.18	9.04 cells/million T-cells Standard Deviation 120.34	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IFN-γ - A/Indonesia, Month 12 + 7 Days	13.38 cells/million T-cells Standard Deviation 163.26	15.65 cells/million T-cells Standard Deviation 111.26	10.25 cells/million T-cells Standard Deviation 163.04	18.89 cells/million T-cells Standard Deviation 170.88	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IFN-γ - A/Vietnam, Month 12 + 7 Days	7.58 cells/million T-cells Standard Deviation 253.61	7.45 cells/million T-cells Standard Deviation 181.01	7.59 cells/million T-cells Standard Deviation 236.89	41.24 cells/million T-cells Standard Deviation 348.65	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IFN-γ - A/Indonesia, Month 12 + 21 Days	13.88 cells/million T-cells Standard Deviation 121.34	7.48 cells/million T-cells Standard Deviation 123.95	6.66 cells/million T-cells Standard Deviation 65.20	13.34 cells/million T-cells Standard Deviation 135.85	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IFN-γ - A/Vietnam, Month 12 + 21 Days	11.90 cells/million T-cells Standard Deviation 273.59	6.84 cells/million T-cells Standard Deviation 235.75	6.18 cells/million T-cells Standard Deviation 111.67	15.18 cells/million T-cells Standard Deviation 269.18	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IFN-γ - A/Indonesia, Month 18	8.53 cells/million T-cells Standard Deviation 121.12	12.19 cells/million T-cells Standard Deviation 79.29	7.77 cells/million T-cells Standard Deviation 113.83	6.53 cells/million T-cells Standard Deviation 164.84	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 IFN-γ - A/Vietnam, Month 18	13.33 cells/million T-cells Standard Deviation 342.90	9.36 cells/million T-cells Standard Deviation 182.90	5.10 cells/million T-cells Standard Deviation 351.48	7.33 cells/million T-cells Standard Deviation 135.83	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 TNF-α - A/Vietnam, Day 0	24.58 cells/million T-cells Standard Deviation 437.31	19.36 cells/million T-cells Standard Deviation 258.56	11.36 cells/million T-cells Standard Deviation 179.18	14.50 cells/million T-cells Standard Deviation 136.30	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 TNF-α - A/Vietnam, Month 6	31.78 cells/million T-cells Standard Deviation 296.04	25.01 cells/million T-cells Standard Deviation 272.87	26.33 cells/million T-cells Standard Deviation 205.26	30.46 cells/million T-cells Standard Deviation 172.62	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 TNF-α - A/Indonesia, Month 12	29.30 cells/million T-cells Standard Deviation 263.60	15.38 cells/million T-cells Standard Deviation 263.83	24.41 cells/million T-cells Standard Deviation 194.37	25.59 cells/million T-cells Standard Deviation 330.65	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 TNF-α - A/Vietnam, Month 12	8.92 cells/million T-cells Standard Deviation 240.77	11.32 cells/million T-cells Standard Deviation 106.95	6.46 cells/million T-cells Standard Deviation 81.15	19.46 cells/million T-cells Standard Deviation 337.02	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 TNF-α - A/Indonesia, Month 12 + 7 Days	54.30 cells/million T-cells Standard Deviation 362.16	34.22 cells/million T-cells Standard Deviation 261.37	35.18 cells/million T-cells Standard Deviation 233.51	32.53 cells/million T-cells Standard Deviation 309.18	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 TNF-α - A/Vietnam, Month 12 + 7 Days	10.89 cells/million T-cells Standard Deviation 363.87	17.27 cells/million T-cells Standard Deviation 340.50	8.21 cells/million T-cells Standard Deviation 300.02	44.13 cells/million T-cells Standard Deviation 394.01	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 TNF-α - A/Indonesia, Month 12 + 21 Days	48.83 cells/million T-cells Standard Deviation 375.84	23.41 cells/million T-cells Standard Deviation 155.91	31.57 cells/million T-cells Standard Deviation 210.43	45.94 cells/million T-cells Standard Deviation 281.82	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 TNF-α - A/Vietnam, Month 12 + 21 Days	14.75 cells/million T-cells Standard Deviation 282.33	10.85 cells/million T-cells Standard Deviation 228.98	8.45 cells/million T-cells Standard Deviation 210.82	35.54 cells/million T-cells Standard Deviation 288.39	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 TNF-α - A/Indonesia, Month 18	41.13 cells/million T-cells Standard Deviation 261.84	24.97 cells/million T-cells Standard Deviation 337.40	27.31 cells/million T-cells Standard Deviation 164.07	31.10 cells/million T-cells Standard Deviation 361.58	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD8 TNF-α - A/Vietnam, Month 18	16.41 cells/million T-cells Standard Deviation 310.32	14.16 cells/million T-cells Standard Deviation 217.05	16.70 cells/million T-cells Standard Deviation 368.21	18.60 cells/million T-cells Standard Deviation 170.85	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 All Doubles - A/Vietnam, Month 12	1230.51 cells/million T-cells Standard Deviation 523.55	1093.54 cells/million T-cells Standard Deviation 941.19	1260.93 cells/million T-cells Standard Deviation 1118.44	1224.35 cells/million T-cells Standard Deviation 2953.68	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 All Doubles - A/Indonesia, Month 12 + 21 Days	2837.94 cells/million T-cells Standard Deviation 1587.84	2180.14 cells/million T-cells Standard Deviation 2032.36	3600.62 cells/million T-cells Standard Deviation 2903.90	3221.46 cells/million T-cells Standard Deviation 2824.65	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 All Doubles - A/Vietnam, Month 12 + 21 Days	2651.19 cells/million T-cells Standard Deviation 2181.61	2276.18 cells/million T-cells Standard Deviation 1434.51	3386.98 cells/million T-cells Standard Deviation 3153.08	3603.01 cells/million T-cells Standard Deviation 3804.83	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 All Doubles - A/Vietnam, Month 18	2230.56 cells/million T-cells Standard Deviation 1780.46	1628.90 cells/million T-cells Standard Deviation 2059.72	2972.79 cells/million T-cells Standard Deviation 1797.59	2535.97 cells/million T-cells Standard Deviation 2627.53	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 CD40L - A/Vietnam, Day 0	536.99 cells/million T-cells Standard Deviation 406.96	505.20 cells/million T-cells Standard Deviation 497.95	504.23 cells/million T-cells Standard Deviation 476.25	729.16 cells/million T-cells Standard Deviation 736.68	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 CD40L - A/Vietnam, Month 6	1272.27 cells/million T-cells Standard Deviation 819.74	891.65 cells/million T-cells Standard Deviation 657.93	1659.46 cells/million T-cells Standard Deviation 823.79	1548.04 cells/million T-cells Standard Deviation 918.09	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 CD40L - A/Indonesia, Month 12	1361.91 cells/million T-cells Standard Deviation 670.66	1209.07 cells/million T-cells Standard Deviation 715.01	1610.40 cells/million T-cells Standard Deviation 1079.91	1478.55 cells/million T-cells Standard Deviation 1259.28	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 CD40L - A/Vietnam, Month 12	1189.38 cells/million T-cells Standard Deviation 519.31	1059.77 cells/million T-cells Standard Deviation 917.49	1217.48 cells/million T-cells Standard Deviation 1056.53	1173.39 cells/million T-cells Standard Deviation 2904.15	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 CD40L - A/Indonesia, Month 12 + 7 Days	1968.90 cells/million T-cells Standard Deviation 1594.19	1724.77 cells/million T-cells Standard Deviation 1242.19	2880.43 cells/million T-cells Standard Deviation 1936.74	3101.88 cells/million T-cells Standard Deviation 6940.95	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 CD40L - A/Indonesia, Month 12 + 21 Days	2744.31 cells/million T-cells Standard Deviation 1545.16	2097.74 cells/million T-cells Standard Deviation 1860.85	3431.78 cells/million T-cells Standard Deviation 2897.09	3124.45 cells/million T-cells Standard Deviation 2787.90	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 CD40L - A/Vietnam, Month 12 + 21 Days	2583.09 cells/million T-cells Standard Deviation 2102.23	2184.58 cells/million T-cells Standard Deviation 1371.47	3179.78 cells/million T-cells Standard Deviation 3132.51	3479.95 cells/million T-cells Standard Deviation 3622.29	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 CD40L - A/Indonesia, Month 18	1943.30 cells/million T-cells Standard Deviation 922.92	1532.05 cells/million T-cells Standard Deviation 1186.69	2859.97 cells/million T-cells Standard Deviation 1657.11	2317.11 cells/million T-cells Standard Deviation 1865.51	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 CD40L - A/Vietnam, Month 18	2174.81 cells/million T-cells Standard Deviation 1734.47	1755.83 cells/million T-cells Standard Deviation 1930.06	2849.08 cells/million T-cells Standard Deviation 1755.65	2483.47 cells/million T-cells Standard Deviation 2583.46	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IL-2 - A/Vietnam, Day 0	376.07 cells/million T-cells Standard Deviation 336.28	409.33 cells/million T-cells Standard Deviation 480.49	436.65 cells/million T-cells Standard Deviation 411.16	612.11 cells/million T-cells Standard Deviation 632.55	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IL-2 - A/Vietnam, Month 6	1097.97 cells/million T-cells Standard Deviation 712.55	804.03 cells/million T-cells Standard Deviation 632.15	1461.85 cells/million T-cells Standard Deviation 769.17	1403.84 cells/million T-cells Standard Deviation 915.32	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IL-2 - A/Vietnam, Month 12	992.70 cells/million T-cells Standard Deviation 427.17	814.08 cells/million T-cells Standard Deviation 714.13	1083.65 cells/million T-cells Standard Deviation 1008.19	1048.97 cells/million T-cells Standard Deviation 2636.29	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IL-2 - A/Indonesia, Month 12 + 7 Days	1498.36 cells/million T-cells Standard Deviation 1396.73	1476.33 cells/million T-cells Standard Deviation 1015.37	2543.33 cells/million T-cells Standard Deviation 1712.80	2670.96 cells/million T-cells Standard Deviation 5571.66	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IL-2 - A/Indonesia, Month 12 + 21 Days	2392.88 cells/million T-cells Standard Deviation 1398.76	1858.04 cells/million T-cells Standard Deviation 1721.69	3108.60 cells/million T-cells Standard Deviation 2632.60	2747.73 cells/million T-cells Standard Deviation 2516.72	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IL-2 - A/Vietnam, Month 12 + 21 Days	2268.27 cells/million T-cells Standard Deviation 1995.17	1932.19 cells/million T-cells Standard Deviation 1276.22	2992.35 cells/million T-cells Standard Deviation 2869.19	3105.21 cells/million T-cells Standard Deviation 3366.65	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IL-2 - A/Indonesia, Month 18	1703.60 cells/million T-cells Standard Deviation 838.53	1383.29 cells/million T-cells Standard Deviation 1077.39	2559.41 cells/million T-cells Standard Deviation 1683.14	2104.29 cells/million T-cells Standard Deviation 1607.98	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IL-2 - A/Vietnam, Month 18	1869.31 cells/million T-cells Standard Deviation 1525.68	1394.95 cells/million T-cells Standard Deviation 1933.81	2589.97 cells/million T-cells Standard Deviation 1776.18	2162.08 cells/million T-cells Standard Deviation 2461.02	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IFN-γ - A/Vietnam, Month 6	690.45 cells/million T-cells Standard Deviation 600.77	539.79 cells/million T-cells Standard Deviation 432.94	771.40 cells/million T-cells Standard Deviation 459.71	748.72 cells/million T-cells Standard Deviation 758.34	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IFN-γ - A/Vietnam, Month 12	729.77 cells/million T-cells Standard Deviation 345.26	565.44 cells/million T-cells Standard Deviation 574.28	633.07 cells/million T-cells Standard Deviation 650.52	767.14 cells/million T-cells Standard Deviation 1198.67	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IFN-γ - A/Indonesia, Month 12 + 7 Days	973.45 cells/million T-cells Standard Deviation 756.29	812.11 cells/million T-cells Standard Deviation 693.80	1308.07 cells/million T-cells Standard Deviation 966.01	1560.86 cells/million T-cells Standard Deviation 2907.99	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IFN-γ - A/Vietnam, Month 12 + 21 Days	1278.22 cells/million T-cells Standard Deviation 1209.43	1074.61 cells/million T-cells Standard Deviation 717.53	1539.76 cells/million T-cells Standard Deviation 1287.82	1795.04 cells/million T-cells Standard Deviation 2122.78	—	—	—	—
Frequency of Influenza-specific CD4/CD8 T-cells (Per 10E6 T-cells) in Tests Identified as Producing at Least Two Out of Four Different Cytokines, for Groups Who Received Booster Dose at Month 12 CD4 IFN-γ - A/Indonesia, Month 18	1113.27 cells/million T-cells Standard Deviation 598.27	902.31 cells/million T-cells Standard Deviation 742.69	1329.00 cells/million T-cells Standard Deviation 814.58	1292.88 cells/million T-cells Standard Deviation 1081.31	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0, Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days and Month 12

GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=56 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=50 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Vietnam, Day 0	20.4 Titers Interval 16.9 to 24.8	22.2 Titers Interval 17.8 to 27.6	18.9 Titers Interval 15.8 to 22.7	19.8 Titers Interval 16.2 to 24.1	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Vietnam, Day 21	117.9 Titers Interval 91.8 to 151.5	106.7 Titers Interval 86.7 to 131.2	179.6 Titers Interval 93.5 to 345.0	78.8 Titers Interval 28.3 to 219.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Vietnam, Day 42	—	—	372.3 Titers Interval 286.5 to 483.8	429.8 Titers Interval 319.1 to 578.9	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Vietnam, Month 6	39.7 Titers Interval 30.8 to 51.0	39.2 Titers Interval 31.2 to 49.2	88.8 Titers Interval 64.0 to 123.1	91.2 Titers Interval 71.8 to 115.9	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 7 Days	778.7 Titers Interval 623.8 to 972.1	1113.9 Titers Interval 857.8 to 1446.5	945.3 Titers Interval 729.8 to 1224.5	1058.8 Titers Interval 828.7 to 1352.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 21 Days	1392.3 Titers Interval 1065.5 to 1819.2	1435.9 Titers Interval 1074.8 to 1918.4	1922.0 Titers Interval 1436.1 to 2572.4	1625.2 Titers Interval 1192.6 to 2214.6	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Vietnam, Month 12	646.3 Titers Interval 539.0 to 775.0	762.9 Titers Interval 611.3 to 952.1	795.6 Titers Interval 577.1 to 1097.0	823.6 Titers Interval 600.5 to 1129.6	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Indonesia, Day 0	15.7 Titers Interval 14.5 to 17.0	15.5 Titers Interval 13.9 to 17.2	15.4 Titers Interval 14.1 to 16.9	14.4 Titers Interval 13.8 to 15.0	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Indonesia, Day 21	39.8 Titers Interval 32.4 to 48.8	32.0 Titers Interval 26.6 to 38.5	37.9 Titers Interval 18.1 to 79.6	33.3 Titers Interval 19.1 to 58.2	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Indonesia, Day 42	—	—	87.9 Titers Interval 68.1 to 113.4	75.9 Titers Interval 59.4 to 96.9	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 7 Days	966.7 Titers Interval 762.0 to 1226.3	512.4 Titers Interval 411.8 to 637.6	1016.1 Titers Interval 759.5 to 1359.4	562.0 Titers Interval 457.2 to 690.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 21 Days	1815.5 Titers Interval 1368.0 to 2409.3	674.4 Titers Interval 536.9 to 847.1	2334.1 Titers Interval 1712.4 to 3181.4	831.3 Titers Interval 644.7 to 1071.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Indonesia, Month 12	672.9 Titers Interval 527.4 to 858.7	392.1 Titers Interval 329.2 to 467.0	1003.8 Titers Interval 751.2 to 1341.4	540.0 Titers Interval 406.6 to 717.3	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 6 A/Indonesia, Month 6	22.0 Titers Interval 18.2 to 26.6	21.7 Titers Interval 18.1 to 25.9	41.7 Titers Interval 31.2 to 55.7	30.5 Titers Interval 23.7 to 39.3	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days and Month 12 + 21 Days

GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=59 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=60 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Indonesia, Day 0	15.8 Titers Interval 14.3 to 17.5	15.7 Titers Interval 14.4 to 17.2	15.1 Titers Interval 14.0 to 16.3	15.5 Titers Interval 14.1 to 17.0	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Indonesia, Day 21	43.5 Titers Interval 35.0 to 54.0	37.0 Titers Interval 29.2 to 46.8	31.3 Titers Interval 18.3 to 53.5	26.5 Titers Interval 17.1 to 41.0	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Indonesia, Day 42	—	—	97.0 Titers Interval 71.2 to 132.1	83.6 Titers Interval 67.8 to 103.0	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Indonesia, Month 6	144.2 Titers Interval 107.2 to 194.0	122.4 Titers Interval 99.2 to 150.9	259.6 Titers Interval 195.6 to 344.5	196.3 Titers Interval 165.1 to 233.5	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Indonesia, Month 12	124.7 Titers Interval 93.8 to 165.8	106.5 Titers Interval 80.2 to 141.5	234.6 Titers Interval 196.7 to 279.9	197.5 Titers Interval 155.0 to 251.6	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	2025.2 Titers Interval 1505.1 to 2725.1	936.9 Titers Interval 730.9 to 1200.9	2556.6 Titers Interval 1917.7 to 3408.4	1102.4 Titers Interval 770.2 to 1577.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	3254.2 Titers Interval 2325.5 to 4553.9	1301.5 Titers Interval 984.4 to 1720.7	4602.2 Titers Interval 3621.0 to 5849.3	1708.3 Titers Interval 1277.3 to 2284.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Vietnam, Day 0	21.0 Titers Interval 17.2 to 25.5	20.6 Titers Interval 17.7 to 23.9	20.3 Titers Interval 16.7 to 24.6	20.0 Titers Interval 16.4 to 24.3	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Vietnam, Day 21	124.4 Titers Interval 93.8 to 165.1	99.2 Titers Interval 80.2 to 122.6	80.2 Titers Interval 49.5 to 129.9	104.6 Titers Interval 35.3 to 310.0	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Vietnam, Day 42	—	—	500.2 Titers Interval 360.5 to 693.9	404.4 Titers Interval 321.5 to 508.7	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Vietnam, Month 6	270.6 Titers Interval 216.5 to 338.2	223.2 Titers Interval 191.7 to 259.9	401.9 Titers Interval 302.2 to 534.4	334.2 Titers Interval 267.0 to 418.3	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Vietnam, Month 12	551.9 Titers Interval 431.3 to 706.4	504.0 Titers Interval 412.6 to 615.7	474.3 Titers Interval 395.3 to 568.9	468.1 Titers Interval 405.1 to 540.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	1848.1 Titers Interval 1453.8 to 2349.4	1448.5 Titers Interval 1175.5 to 1784.9	2002.2 Titers Interval 1533.7 to 2613.9	1718.1 Titers Interval 1301.3 to 2268.4	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Adults Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	3209.7 Titers Interval 2461.3 to 4185.6	2520.3 Titers Interval 1914.2 to 3318.3	3874.7 Titers Interval 2944.6 to 5098.5	2304.8 Titers Interval 1747.6 to 3039.5	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0, Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18

Population: The analysis was performed on the ATP Cohort for Persistence, which included all evaluable subjects for whom long term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol. Day 42 data were available only from subjects who received 3 vaccine doses.

GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=51 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=44 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 0	15.7 Titers Interval 14.4 to 17.1	15.3 Titers Interval 13.7 to 17.1	15.5 Titers Interval 14.2 to 17.1	14.4 Titers Interval 13.8 to 15.1	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 21	40.6 Titers Interval 32.5 to 50.6	31.8 Titers Interval 25.9 to 38.9	37.9 Titers Interval 18.1 to 79.6	36.4 Titers Interval 18.6 to 71.1	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 42	—	—	86.3 Titers Interval 66.5 to 111.9	76.7 Titers Interval 61.0 to 96.3	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6	20.7 Titers Interval 17.4 to 24.7	22.2 Titers Interval 18.3 to 26.8	40.9 Titers Interval 30.3 to 55.0	29.2 Titers Interval 22.6 to 37.7	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6+ 7 Days	906.1 Titers Interval 708.4 to 1158.8	526.2 Titers Interval 419.4 to 660.2	963.3 Titers Interval 713.9 to 1299.9	537.3 Titers Interval 431.1 to 669.5	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 21 Days	1703.0 Titers Interval 1263.7 to 2295.0	707.6 Titers Interval 556.5 to 899.8	2224.0 Titers Interval 1613.6 to 3065.3	814.7 Titers Interval 629.8 to 1053.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 12	678.0 Titers Interval 525.5 to 874.7	392.1 Titers Interval 329.2 to 467.0	995.8 Titers Interval 740.6 to 1339.0	533.4 Titers Interval 399.2 to 712.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 18	361.1 Titers Interval 283.8 to 459.6	225.0 Titers Interval 175.0 to 289.2	447.6 Titers Interval 345.2 to 580.5	290.1 Titers Interval 211.1 to 398.7	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 0	20.9 Titers Interval 17.0 to 25.8	22.0 Titers Interval 17.5 to 27.6	19.3 Titers Interval 16.0 to 23.4	20.4 Titers Interval 16.5 to 25.2	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 21	119.0 Titers Interval 91.5 to 154.7	109.0 Titers Interval 87.2 to 136.2	179.6 Titers Interval 93.5 to 345.0	103.6 Titers Interval 30.4 to 352.5	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 42	—	—	352.9 Titers Interval 272.3 to 457.4	449.3 Titers Interval 338.8 to 596.0	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 7 Days	727.6 Titers Interval 579.8 to 913.0	1167.5 Titers Interval 893.0 to 1526.2	910.3 Titers Interval 700.4 to 1183.1	1035.0 Titers Interval 794.6 to 1348.1	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 21 Days	1296.1 Titers Interval 985.1 to 1705.3	1568.2 Titers Interval 1176.0 to 2091.2	1863.6 Titers Interval 1387.9 to 2502.4	1609.1 Titers Interval 1162.2 to 2227.7	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 12	643.3 Titers Interval 532.4 to 777.4	762.9 Titers Interval 611.3 to 952.1	797.7 Titers Interval 574.3 to 1107.9	844.7 Titers Interval 613.7 to 1162.7	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 18	277.7 Titers Interval 208.2 to 370.3	338.1 Titers Interval 254.2 to 449.6	358.9 Titers Interval 254.4 to 506.2	444.5 Titers Interval 310.4 to 636.6	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6	35.9 Titers Interval 28.2 to 45.6	39.8 Titers Interval 31.1 to 51.0	86.1 Titers Interval 61.6 to 120.4	91.4 Titers Interval 72.2 to 115.6	—	—	—	—

SECONDARY outcome

Timeframe: At Day 0, Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days, Month 12 + 21 Days and Month 18

GMTs were calculated for H5N1 neutralizing antibodies against the A/Vietnam/1194/2004 or A/Indonesia/05/2005 strains.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=53 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=45 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Day 0	15.9 Titer Interval 14.2 to 17.9	15.6 Titer Interval 14.3 to 17.1	15.4 Titer Interval 14.0 to 16.9	15.7 Titer Interval 14.1 to 17.5	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Day 21	45.1 Titer Interval 35.4 to 57.4	40.0 Titer Interval 31.1 to 51.5	31.3 Titer Interval 18.3 to 53.5	26.3 Titer Interval 16.1 to 43.0	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Day 42	—	—	100.8 Titer Interval 68.6 to 148.1	80.7 Titer Interval 65.4 to 99.6	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 6	146.5 Titer Interval 108.3 to 198.0	123.3 Titer Interval 99.6 to 152.6	255.0 Titer Interval 188.5 to 345.0	196.3 Titer Interval 165.1 to 233.5	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12	127.0 Titer Interval 95.7 to 168.5	107.8 Titer Interval 80.5 to 144.3	231.3 Titer Interval 191.6 to 279.3	197.5 Titer Interval 155.0 to 251.6	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	2190.6 Titer Interval 1657.3 to 2895.6	947.5 Titer Interval 732.7 to 1225.4	2476.1 Titer Interval 1839.2 to 3333.5	1102.4 Titer Interval 770.2 to 1577.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	3722.1 Titer Interval 2850.5 to 4860.1	1303.0 Titer Interval 975.7 to 1740.0	4661.0 Titer Interval 3625.1 to 5993.0	1708.3 Titer Interval 1277.3 to 2284.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 18	903.0 Titer Interval 667.6 to 1221.5	423.7 Titer Interval 320.9 to 559.5	1708.9 Titer Interval 1243.6 to 2348.4	620.6 Titer Interval 475.5 to 809.9	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Day 0	20.5 Titer Interval 16.5 to 25.4	20.8 Titer Interval 17.7 to 24.5	20.8 Titer Interval 16.6 to 26.1	20.5 Titer Interval 16.5 to 25.4	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Day 21	123.7 Titer Interval 93.6 to 163.6	103.6 Titer Interval 82.1 to 130.8	80.2 Titer Interval 49.5 to 129.9	116.2 Titer Interval 33.9 to 398.1	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Day 42	—	—	469.2 Titer Interval 321.4 to 684.8	399.2 Titer Interval 321.7 to 495.4	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 6	274.5 Titer Interval 218.3 to 345.4	223.1 Titer Interval 190.4 to 261.4	405.1 Titer Interval 298.8 to 549.3	334.2 Titer Interval 267.0 to 418.3	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12	542.7 Titer Interval 417.6 to 705.2	511.2 Titer Interval 415.6 to 628.9	475.9 Titer Interval 393.1 to 576.1	468.1 Titer Interval 405.1 to 540.8	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	1945.3 Titer Interval 1532.8 to 2468.9	1435.4 Titer Interval 1163.3 to 1771.1	1972.2 Titer Interval 1490.9 to 2609.0	1718.1 Titer Interval 1301.3 to 2268.4	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	3490.4 Titer Interval 2712.8 to 4491.0	2495.4 Titer Interval 1886.4 to 3300.9	4057.4 Titer Interval 3048.1 to 5400.9	2304.8 Titer Interval 1747.6 to 3039.5	—	—	—	—
GMTs of H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 18	813.2 Titer Interval 580.8 to 1138.5	585.9 Titer Interval 417.5 to 822.2	1650.0 Titer Interval 1203.4 to 2262.4	871.9 Titer Interval 621.0 to 1224.2	—	—	—	—

SECONDARY outcome

Timeframe: At Day 21, Day 42, Month 6, Month 6 + 7 Days, Month 6 + 21 Days and Month 12

Seroconversion (SCR) was defined as the percentage of vaccinees with a minimum 4-fold increase in neutralizing antibody titer at the post-vaccination time-point compared to Day 0. The 2 flu strains assessed were A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1).

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=56 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=55 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=49 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 21	19 Participants	13 Participants	1 Participants	4 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Day 42	—	—	32 Participants	28 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6	6 Participants	5 Participants	20 Participants	13 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 7 Days	53 Participants	46 Participants	48 Participants	46 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 21 Days	51 Participants	47 Participants	49 Participants	43 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 12	47 Participants	42 Participants	46 Participants	42 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 21	40 Participants	34 Participants	5 Participants	5 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Day 42	—	—	42 Participants	39 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6	18 Participants	10 Participants	28 Participants	31 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 7 Days	51 Participants	45 Participants	48 Participants	45 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 21 Days	52 Participants	45 Participants	49 Participants	45 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 12	47 Participants	42 Participants	45 Participants	42 Participants	—	—	—	—

SECONDARY outcome

Timeframe: At Day 21, Day 42, Month 6, Month 12, Month 12 + 7 Days and Month 12 + 21 Days

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=58 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=60 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Day 21	19 Participants	17 Participants	1 Participants	1 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Day 42	—	—	35 Participants	32 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 6	45 Participants	44 Participants	43 Participants	44 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12	41 Participants	39 Participants	42 Participants	40 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	51 Participants	49 Participants	42 Participants	40 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	50 Participants	50 Participants	43 Participants	40 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	50 Participants	49 Participants	41 Participants	40 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	51 Participants	50 Participants	42 Participants	39 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Day 21	40 Participants	38 Participants	4 Participants	5 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Day 42	—	—	43 Participants	45 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 6	51 Participants	50 Participants	40 Participants	41 Participants	—	—	—	—
Number of Seroconverted Subjects for H5N1 Neutralizing Antibodies Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12	48 Participants	49 Participants	43 Participants	40 Participants	—	—	—	—

SECONDARY outcome

Timeframe: At Month 6 + 7 Days, Month 6 + 21 Days, Month 12 and Month 18

Population: This analysis was performed on the ATP Cohort for Immunogenicity (only for M12) and ATP Cohort for Persistence, which included all evaluable subjects for whom immunogenicity data/long term immunogenicity data were available and who complied with the inclusion/exclusion criteria as defined in the protocol.

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=42 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=46 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=43 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 21 Days	46 Participants	41 Participants	45 Participants	39 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 18	40 Participants	32 Participants	38 Participants	32 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 7 Days	44 Participants	40 Participants	35 Participants	38 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 6 + 21 Days	46 Participants	41 Participants	39 Participants	40 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 12	46 Participants	39 Participants	33 Participants	36 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Vietnam, Month 18	33 Participants	35 Participants	26 Participants	27 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 6 + 7 Days	48 Participants	41 Participants	43 Participants	41 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 6 A/Indonesia, Month 12	47 Participants	40 Participants	44 Participants	41 Participants	—	—	—	—

SECONDARY outcome

Timeframe: At Month 12 + 7 Days and Month 12 + 21 Days

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=51 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=50 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=43 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=40 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	46 Participants	39 Participants	42 Participants	29 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	17 Participants	16 Participants	18 Participants	19 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	31 Participants	25 Participants	31 Participants	21 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	42 Participants	35 Participants	34 Participants	20 Participants	—	—	—	—

SECONDARY outcome

Timeframe: At Month 12 + 7 Days, Month 12 + 21 Days and Month 18

Outcome measures

Outcome measures
Measure	GSK1562902A V/I/6 Group n=47 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=48 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=40 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=40 Participants Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 7 Days	39 Participants	34 Participants	32 Participants	20 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 12 + 21 Days	44 Participants	38 Participants	39 Participants	29 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Indonesia, Month 18	33 Participants	25 Participants	31 Participants	18 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 7 Days	15 Participants	15 Participants	17 Participants	19 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 12 + 21 Days	30 Participants	23 Participants	29 Participants	21 Participants	—	—	—	—
Number of Booster Seroconverted Subjects Against 2 Strains of Influenza Disease, for Groups Who Received Booster Dose at Month 12 A/Vietnam, Month 18	8 Participants	7 Participants	16 Participants	10 Participants	—	—	—	—

Adverse Events

GSK1562902A V/I/6 Group

Serious events: 4 serious events

Other events: 58 other events

Deaths: 0 deaths

GSK1562902A V/V/6 Group

Serious events: 1 serious events

Other events: 65 other events

Deaths: 0 deaths

GSK1562902A 2V/I/6 Group

Serious events: 0 serious events

Other events: 63 other events

Deaths: 0 deaths

GSK1562902A 2V/V/6 Group

Serious events: 3 serious events

Other events: 61 other events

Deaths: 0 deaths

GSK1562902A V/I/12 Group

Serious events: 1 serious events

Other events: 61 other events

Deaths: 0 deaths

GSK1562902A V/V/12 Group

Serious events: 5 serious events

Other events: 60 other events

Deaths: 1 deaths

GSK1562902A 2V/I/12 Group

Serious events: 1 serious events

Other events: 65 other events

Deaths: 0 deaths

GSK1562902A 2V/V/12 Group

Serious events: 3 serious events

Other events: 62 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	GSK1562902A V/I/6 Group n=63 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=66 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=64 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=63 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group n=64 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group n=64 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group n=65 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group n=63 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Cardiac disorders Myocardial infarction	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Cardiac disorders Sick sinus syndrome	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Infections and infestations Cellulitis	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.5% 1/66 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Infections and infestations Tonsillitis	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Injury, poisoning and procedural complications Concussion	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Injury, poisoning and procedural complications Skin laceration	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Injury, poisoning and procedural complications Soft tissue injury	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Injury, poisoning and procedural complications Traumatic brain injury	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/64 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/64 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Leiomyoma	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/64 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-hodgkin's lymphoma	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/64 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine neoplasm	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.5% 1/65 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Nervous system disorders Cerebral infarction	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/64 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Nervous system disorders Cervicobrachial syndrome	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/64 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Nervous system disorders Hemiparesis	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/64 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Nervous system disorders Hypoaesthesia	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Nervous system disorders Multiple sclerosis	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Reproductive system and breast disorders Uterine polyp	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/66 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/65 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).

Other adverse events

Other adverse events
Measure	GSK1562902A V/I/6 Group n=63 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/6 Group n=66 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/6 Group n=64 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/6 Group n=63 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/I/12 Group n=64 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 1 dose of vaccine formulated from VT (A/Vietnam/1994/2004) strain at Day 0 and 1 dose of the vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A V/V/12 Group n=64 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/I/12 Group n=65 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN (A/Indonesia/05/2005) strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.	GSK1562902A 2V/V/12 Group n=63 participants at risk Healthy male or female subjects, between and including 18 and 60 years of age, who received 2 doses of vaccine formulated from VT (A/Vietnam/1994/2004) strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
Infections and infestations Nasopharyngitis	12.7% 8/63 • Number of events 10 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	7.6% 5/66 • Number of events 5 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	10.9% 7/64 • Number of events 7 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	17.5% 11/63 • Number of events 12 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	12.5% 8/64 • Number of events 8 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	12.5% 8/64 • Number of events 8 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	15.4% 10/65 • Number of events 11 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	7.9% 5/63 • Number of events 5 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Musculoskeletal and connective tissue disorders Arthralgia	27.0% 17/63 • Number of events 20 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	39.4% 26/66 • Number of events 34 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	42.2% 27/64 • Number of events 40 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	44.4% 28/63 • Number of events 47 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	31.2% 20/64 • Number of events 28 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	20.3% 13/64 • Number of events 21 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	44.6% 29/65 • Number of events 43 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	41.3% 26/63 • Number of events 35 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
General disorders Chills	34.9% 22/63 • Number of events 27 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	42.4% 28/66 • Number of events 33 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	37.5% 24/64 • Number of events 37 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	57.1% 36/63 • Number of events 53 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	34.4% 22/64 • Number of events 32 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	31.2% 20/64 • Number of events 24 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	38.5% 25/65 • Number of events 36 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	46.0% 29/63 • Number of events 49 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Gastrointestinal disorders Diarrhoea	3.2% 2/63 • Number of events 2 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.5% 1/66 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/64 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/64 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	3.1% 2/64 • Number of events 2 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	3.1% 2/65 • Number of events 2 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	6.3% 4/63 • Number of events 4 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Skin and subcutaneous tissue disorders Ecchymosis	3.2% 2/63 • Number of events 2 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.5% 1/66 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	3.1% 2/64 • Number of events 2 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	3.1% 2/64 • Number of events 2 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	6.2% 4/65 • Number of events 4 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	1.6% 1/63 • Number of events 1 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Skin and subcutaneous tissue disorders Erythema	17.5% 11/63 • Number of events 13 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	12.1% 8/66 • Number of events 14 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	25.0% 16/64 • Number of events 24 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	20.6% 13/63 • Number of events 22 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	12.5% 8/64 • Number of events 10 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	17.2% 11/64 • Number of events 15 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	20.0% 13/65 • Number of events 21 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	23.8% 15/63 • Number of events 21 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
General disorders Fatigue	55.6% 35/63 • Number of events 48 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	56.1% 37/66 • Number of events 54 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	70.3% 45/64 • Number of events 84 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	69.8% 44/63 • Number of events 77 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	57.8% 37/64 • Number of events 57 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	51.6% 33/64 • Number of events 43 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	72.3% 47/65 • Number of events 75 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	69.8% 44/63 • Number of events 81 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Nervous system disorders Headache	55.6% 35/63 • Number of events 47 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	51.5% 34/66 • Number of events 48 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	65.6% 42/64 • Number of events 78 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	66.7% 42/63 • Number of events 83 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	50.0% 32/64 • Number of events 48 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	53.1% 34/64 • Number of events 47 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	69.2% 45/65 • Number of events 76 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	65.1% 41/63 • Number of events 71 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Skin and subcutaneous tissue disorders Hyperhidrosis	23.8% 15/63 • Number of events 16 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	27.3% 18/66 • Number of events 19 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	35.9% 23/64 • Number of events 34 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	31.7% 20/63 • Number of events 30 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	25.0% 16/64 • Number of events 18 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	10.9% 7/64 • Number of events 8 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	35.4% 23/65 • Number of events 29 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	39.7% 25/63 • Number of events 34 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
General disorders Induration	27.0% 17/63 • Number of events 22 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	19.7% 13/66 • Number of events 20 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	34.4% 22/64 • Number of events 35 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	39.7% 25/63 • Number of events 47 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	21.9% 14/64 • Number of events 18 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	25.0% 16/64 • Number of events 20 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	36.9% 24/65 • Number of events 38 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	30.2% 19/63 • Number of events 26 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/63 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	4.5% 3/66 • Number of events 3 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	3.1% 2/64 • Number of events 3 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	4.8% 3/63 • Number of events 3 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	4.7% 3/64 • Number of events 4 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	0.00% 0/64 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	6.2% 4/65 • Number of events 4 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	4.8% 3/63 • Number of events 4 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
Musculoskeletal and connective tissue disorders Myalgia	65.1% 41/63 • Number of events 57 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	62.1% 41/66 • Number of events 61 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	75.0% 48/64 • Number of events 94 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	76.2% 48/63 • Number of events 92 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	76.6% 49/64 • Number of events 71 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	64.1% 41/64 • Number of events 60 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	69.2% 45/65 • Number of events 87 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	74.6% 47/63 • Number of events 88 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
General disorders Pain	88.9% 56/63 • Number of events 96 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	93.9% 62/66 • Number of events 111 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	95.3% 61/64 • Number of events 157 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	93.7% 59/63 • Number of events 156 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	95.3% 61/64 • Number of events 107 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	89.1% 57/64 • Number of events 99 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	95.4% 62/65 • Number of events 154 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	92.1% 58/63 • Number of events 145 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
General disorders Pyrexia	9.5% 6/63 • Number of events 6 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	4.5% 3/66 • Number of events 4 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	6.2% 4/64 • Number of events 4 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	6.3% 4/63 • Number of events 4 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	7.8% 5/64 • Number of events 5 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	10.9% 7/64 • Number of events 8 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	7.7% 5/65 • Number of events 6 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	7.9% 5/63 • Number of events 6 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).
General disorders Swelling	19.0% 12/63 • Number of events 14 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	22.7% 15/66 • Number of events 19 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	32.8% 21/64 • Number of events 32 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	34.9% 22/63 • Number of events 37 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	15.6% 10/64 • Number of events 11 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	20.3% 13/64 • Number of events 17 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	24.6% 16/65 • Number of events 22 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).	25.4% 16/63 • Number of events 27 • Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-primary and booster vaccination period; SAEs: during the entire study period (from Day 0 up to Month 18).

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER